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Liver cirrhosis is the fifth leading cause of death worldwide and the definitive treatment for 
liver cirrhosis is liver transplantation although there are limitations such as organ availability 
and surgical risks. Therefore, alternative therapies have been studied extensively and stem cell 
therapies have shown some promising results although most studies are small and not 
randomised.  
The aim of this thesis was to explore the effectiveness of stem cell therapy in patients with 
chronic liver disease as well as explore the mechanism behind fibrosis resolution achieved with 
cell therapy. 
There were three parts to the thesis: firstly, I examined the mechanistic actions behind fibrosis 
reduction by the infusion of bone marrow derived haematopoietic stem cells (HSC) in mice 
chronic fibrosis liver injury model. I worked on both immune-histochemical staining and qPCR 
to measure the effect oval cell response, matrix metalloproteinases and macrophage subsets 
within the liver with HSC therapies.   
Secondly, I recruited patients with chronic liver diseases for a multicentre, randomised, 
controlled trial to assess the clinical effectiveness of either subcutaneous granulocyte-colony 
stimulating factor (GCSF) or GCSF with repeated HSC infusions. The co-primary outcomes 
were improvement in severity of liver disease measured by model for end stage live disease 
(MELD) at 3 months and the trend of MELD change over time. The results showed that neither 
of the treatments improved the clinical outcomes.  
Lastly, I performed a systematic review of current published studies of stem cells therapies in 
liver diseases. The results showed that stem cells improved patients’ clinical parameters in the 
short term (<6 months) but had no benefit on long term outcomes.   
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1.1: Anatomy of the liver 
 
The liver is the largest organ in the body and is found in the right upper abdominal region. 
There are 2 anatomical lobes in liver, as in the right and left lobe. Within the right lobe segment, 
the caudate lobe is found on the posterior surface of the liver and the quadrate lobe is on the 
inferior surface (Figure 1) (1).  The functional liver unit consists of the hepatic lobule which 
has a central vein and hexagonal portal trials including portal vein, hepatic artery and bile duct 
(2). The central vein is connected to the portal trails vis sinusoids that run through the hepatic 
plates (2). The liver has dual blood supplies; 80% of the blood supply comes from the portal 
vein and 20% from the hepatic artery (1). The portal vein brings venous blood from the gut, 
pancreas and spleen and supplies low oxygenation venous blood which is high in nutrition and 
toxin content (1) . The liver receives arterial blood from the hepatic artery which arises from 
the coeliac axis (1). Bloods drain from sinusoids between the hepatocytes into the hepatic vein 
and subsequently into the inferior vena cava (Figure 2) (1).  
1.2: Functions of the liver 
 
The liver is essential for a wide variety of functions including glucose metabolism through 
glycogenolysis and gluconeogenesis, synthesis and excretion of bile acids, synthesis of plasma 
proteins such as albumin, production of clotting factors, metabolism of nitrogenous waste 
products, cholesterol and steroid hormone metabolism (1, 2). In addition, the liver removes 
toxins from the blood stream, metabolises pharmacological drugs and regulates the immune 
system (1, 2). Peri-portal hepatocytes are involved mainly in oxidative liver functions such as 
gluconeogenesis, beta-oxidation of fatty acids, cholesterol synthesis while peri-central 
hepatocytes are more specialised for glycolysis, lipogenesis and cytochrome p450 based drug 




Figure 1: Anatomy of the anterior view of the liver (1) 
 
 








In the United Kingdom (UK), liver disease is currently the third commonest cause of premature 
death and the rate is considerably higher than other European countries (4). Liver injury is 
caused by either an acute insult (as in paracetamol overdose) or ongoing chronic injury. Acute 
liver injury results occurs when there is a rapid, massive hepatocyte cell deaths which leads to 
significant impairment in liver function and hence is associated with a high mortality rate (5). 
In chronic liver injury, there is a progressive loss of hepatocytes that lasts from months to 
decades (5).  
According to World Health Organisation (WHO) data, liver cirrhosis accounted for 1.8% of all 
deaths in Europe, causing around 170,000 deaths per year (6). Among northern European 
countries, there was a 2-fold increase in the rate of liver cirrhosis in UK and Ireland (6). Liver 
disease causes approximately 2% of all deaths (7) and liver disease related mortality has been 
rising steadily since 2001 (Figure 3). Hepatocellular carcinoma (HCC) is the fifth common 
cause of cancer and accounts for 70-90% of primary liver cancer (6). Without any treatment, 
5-year survival of patient with HCC is around 5% (6).  
Liver cirrhosis represents end stage liver damage irrespective of the underlying aetiology.  In 
the UK, alcohol related liver disease (ARLD) accounts for well over a third of liver disease [6] 
although in recent years, the incidence of non-alcoholic fatty liver disease (NAFLD) has risen 
due to the increased incidence of obesity worldwide. NAFLD is usually associated with other 
metabolic risk factors such as diabetes and hypercholesterolemia [7, 8]. The underlying causes 
for liver cirrhosis had mentioned in Table 1.  
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Currently, the definitive treatment for acute liver failure, decompensated liver cirrhosis and 
liver cancer is liver transplantation (LT) although it is associated with certain limitations.  
 
Figure 3: Mortality caused by liver cirrhosis in England from year 2001 to 2009 (Reproduced 




Table 1: Causes of liver cirrhosis 
Causes of liver cirrhosis 
▪ Alcohol excess 
▪ Chronic viral hepatitis 
o Hepatitis B and C 
▪ Autoimmune liver disease 
o Autoimmune hepatitis 
o Primary biliary cholangitis 
o Primary sclerosing cholangitis 
▪ Non-alcoholic fatty liver disease (associated with metabolic syndrome: diabetes, 
hypercholesterolemia, obesity and hypertension) 
▪ Genetic  
o Haemochromatosis 
▪ Drugs induced 
▪ Vascular causes  
o Budd Chiari 
 
2.2: Pathophysiology of liver fibrosis and regeneration  
 
The liver is a unique organ with an extraordinary ability to regenerate when exposed to various 
insults and the regeneration is contributed mostly by mature hepatocytes with their rapid cell 
turnover (2, 5). Regenerative capacity of the liver is well known and in 1993, Higgins and 
Anderson (8) developed an experimental model of liver regeneration in which they surgically 
removed two thirds of liver mass. Since then, partial hepatectomy is routinely performed as a 
standard surgical procedure in clinical practice. In the case of hepatectomy, liver regenerate to 
compensate for the volume loss, also known as compensatory hyperplasia (2).  
 The pathogenesis behind liver fibrosis a complex mechanism but in recent years, there has 
been a better understanding of liver fibrogensis as well as fibrinolysis process. In a healthy 
liver, extracellular matrix (ECM) is present within the space of Disse, the space between 
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endothelial cells ad hepatocytes, mainly consists of collagen IV and V [8, 10].  ECM is a highly 
dynamic non-cellular structure that undergoes controlled remodelling constantly and it 
interacts with epithelial cells to regulate functions such as proliferation, migration and 
differentiation (9). This process of remodelling is complex and need to be regulated tightly to 
maintain tissue homeostasis, especially in response to injury (9). The cleavage of ECM 
components is the main process during ECM remodelling and is important for regulating ECM 
composition and structure(9). If there is dysregulation of ECM remodelling, the disease 
progress further to fibrosis and cancer (9). The homeostasis of ECM is tightly regulated by a 
balance between matrix metalloproteinases (MMPs) and their inhibitors known as tissue 
inhibitors of metalloproteinases (TIMPSs) [11].  MMPs are secreted as zymogens and are 
usually low in normal liver but increased during repair or remodelling process in injured tissue 
(9). Upregulation of TIMP-1 in the fibrotic liver contribute to collagen deposition by inhibiting 
the resolution of ECM (2).  
After an acute insult to the liver, the necrotic or apoptotic cells will be replaced by regenerative 
parenchymal cells [8]. If the injury is transient, the cells activated by inflammation settle 
eventually, followed by the resolution of ECM and revascularisation (2). However, in some 
cases, the process of injury far exceeds the capacity of regeneration and in that circumstance, 
liver progenitor cells (LPC), also known as oval cells, that are present within the canals of 
Hering are activated to take over the role of regeneration (5, 10). LPC are bipotential cells and 
they can proliferate into either hepatocyte or cholangiocytes depending on the nature of injury 
(5, 11). The LPC environment includes epithelial cells, hepatic stellate cells, immune cells 
known as Kupffer cells and the ECM (5). Upon amplification, LPC infiltrate along the liver 
plate towards the central vein and differentiate into hepatocytes to restore liver function and 
cell mass (5).  
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In chronic liver injury, hepatic stellate cells (HSCs) became activated and differentiate into 
fibroblast like cells leading to an excessive deposition of collagen [11]. Activation of HSCs is 
stimulated by damaged hepatocytes through release of reactive oxygen species, cytokines and 
chemokines [10]. In activated HSCs, the expression of TIMP-1 is upregulated leading to the 
inhibition of MMP activity which leads to the accumulation of matrix proteins in the 
extracellular space [8, 11]. One of the pathological features of liver fibrosis is the increased 
expression of collagen, fibronectins, proteoglycans, structural glycoproteins, hyaluronan 
leading to persistent formation on new ECM [11]. In advanced stages of liver disease, there is 
a substantial change is in the deposition of collagens mainly type I, III and IV, fibronectin, 
laminin, hyaluronic acid and proteoglycans which are increased in fibrotic ECM up to 10-fold 
more than normal livers [8, 10, 11]. The simplified diagram of liver fibrosis and resolution of 
is shown in figure 4.  
When fibrosis is established, structural changes in the form of extensive capillarisation of the 
liver sinusoids and the formation of intrahepatic vascular shunts occurs as well as functional 
changes such as endothelial dysfunction which leads to the development of regenerative 
nodules and portal hypertension [10, 11]. The clinical manifestations of this are the 
development of varices, ascites and hepatic encephalopathy (12). The loss of hepatocyte mass 
results in hepatic synthetic dysfunction with low levels of albumin and raised clotting factors 




Figure 4: Simplified schematic view of liver fibrosis pathogenesis and resolution of fibrosis 
 
 
Figure 5: Progression of liver disease after injury to the liver 
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2.3: Clinical features of liver cirrhosis 
 
In compensated cirrhosis, patients have underlying liver cirrhosis but no overt clinical features 
of liver disease. Patients with decompensated cirrhosis present with clinical features such as 
jaundice, ascites, variceal bleeding or hepatic encephalopathy which are the consequence of 
portal hypertension. The transition from compensated to decompensated cirrhosis occurs at a 
rate of approximately 5 to 7% per year (10). Table 2 shows the mortality associated with stages 
of liver cirrhosis based on their clinical features.  
Table 2: Four stages of liver cirrhosis classification (12) 
 Compensated liver cirrhosis Decompensated liver cirrhosis 
 Stage 1 Stage 2 Stage 3 Stage 4 








Mortality at 1 
year 
1% 3% 20% 57% 
 
2.4: Assessment of liver disease progression 
 
The progression and severity of liver disease can be monitored in variety of ways; either 
invasive or non-invasive investigations. The methods used in assessing patients include clinical 
assessment, biochemical measurement, serum fibrosis markers and radiological assessment 
and these are usually used in combination to determine the severity of liver disease. It is 
important to recognise the disease stage as early as possible to prevent the progression of liver 
fibrosis and clinical deterioration.   
Non-invasive investigations include blood tests, radiological assessment including ultrasound, 
computed tomography, magnetic resonance imaging and transient elastography (TE). Routine 
biochemical blood tests that used in patients with liver disease include alanine transaminase 
(ALT), aspartate transaminase (AST), serum bilirubin, serum albumin, international 
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normalised ratio (INR) and platelets. These blood tests are then used to calculate scores that 
can predict the survival of patients. The commonly used scoring systems in clinical settings are 
Model for End-Stage Liver Disease (MELD), United Kingdom Model for End-Stage Liver 
Disease (UKELD) and Child -Turcotte-Pugh Score (CPS). In recent years, TE has been used 
in clinical settings to measure the stiffness of the liver as a surrogate markers of liver fibrosis. 
There are two broad types of serum markers; direct and indirect that are used as a surrogate to 
predict liver fibrosis (13). Direct biomarkers measure the components of ECM as well as the 
enzymes which regulate the matrix: including MMPs, subtypes of collagen and hyaluronic acid 
(14, 15). Indirect markers include parameters such as platelet count as marker of portal 
hypertension, AST and ALT as marker of liver cell inflammation and injury and INR as a 
marker of liver synthetic dysfunction (16, 17). The commonly used biomarkers in clinical 
settings are included in Table 3. 
Table 3: Indirect and direct serum biomarkers of liver fibrosis (13, 18)  
Test Components Formula References 








[AST (U/L)/upper limit of normal (U/L)] 








Sum obtained from three variables (BMI≥ 
28= 1 point, AST/ALT ratio≥ 0.8= 2 points, 
diabetes =1-point, scale varies from 0 to 4) 
(19) 
FIB-4 Age, AST, ALT, 
Platelet 

















+0.0281×[Age(years)] + 1.737× 
log10[Bilirubin (μmol/L)]-
1.184×[ApoA1*(g/L)] +0.301×Sex (female = 









=−1.675 + 0.037×age (years) + 0.094×BMI 
(kg/m2) + 1.13× 
IFG/diabetes (yes = 1, no = 0) + 
0.99×AST/ALT ratio – .013× 
platelet (× 109/l) – 0.66×albumin (g/dl) 
(22) 











−7.412 + [ln(HA)*0.681] + 




2.4 (i): Model for End-Stage Liver Disease (MELD) 
 
Mode for end stage liver disease (MELD) score was originally developed to predict survival 
of cirrhotic patients undergoing elective trans-jugular intrahepatic portosystemic shunt (TIPSS) 
procedure (24). MELD score is calculated using a combination of blood tests: serum creatinine, 
serum bilirubin and international normalised ratio (INR). The score determines the severity of 
underlying CLD and is used to predict how likely the patient will need liver transplantation 
(LT) within the next 3 months (25, 26), as it has been shown to be an accurate predictor of 
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survival in patients with liver disease not undergoing LT (25, 27). The score ranges from a 
minimum of 6 (mild disease) to a maximum of 40 (severe disease) (28). The higher the score, 
the more likely that the patient will have a worse survival (Figure 6) and hence, a higher 
likelihood of requiring liver transplantation. Patients waiting for an LT with a score of 40 have 
a 300-fold increased risk of mortality compared to patients with a score of less than 12 (25, 
29).  
 
Figure 6: Three-month mortality based on model for end stage liver disease (MELD) score (25) 
2.4 (ii): United Kingdom Model for End Stage Liver Disease (UKELD) 
 
UKELD (United Kingdom Model for End-stage Liver Disease) is an another scoring which 
has been used widely in UK to help determine the need for patients to have LT (30). It was 
developed in 2008 and was based on MELD score with incorporation of the serum sodium 
level (30). A UKELD score of 49 indicates a 9% 1-year mortality risk and the minimum score 
required to be added to the LT waiting list in the UK (30, 31). A UKELD score of 60 indicates 




2.4 (iii): Child-Turcotte Pugh Classification  
 
Child Pugh classification is calculated from a combination of objective parameters [serum 
bilirubin, INR or prothrombin time, serum albumin] and subjective parameters [clinical 
assessment of ascites and hepatic encephalopathy] (32, 33). Chid Pugh score (CPS) varies 
between 7 and 15 and the mortality is increased with a higher CPS (34). In table 4 demonstrated 
the parameters that involved in Child Pugh Scoring. The scoring system showed that patients 
with Child C have higher mortality compared to Child A or Child B with 1-year survival of 
45% (Figure 7) (12).  
Table 4: Child-Turcotte Pugh Score classification (33) 
Child Pugh Classification for severity of liver cirrhosis 
 Points 
Parameters 1 2 3 
Hepatic Encephalopathy None Grade 1-2 Grade 3-4 




Bilirubin (umol/L) <34 34-51 >51 
Albumin (g/dL) >35 28-35 <28 
Prothrombin time (seconds) <4 4-6 >6 
Class A: 5-6 points (least severe)  
Class B: 7-9 points (moderately severe) 





Figure 7: Survival in patients with liver diseases as per Child-Turcotte Pugh grades (12) 
 
2.4 (iv): Enhanced liver fibrosis test (ELF) 
 
Enhanced liver fibrosis test (ELF) test is a validated test which includes panels of highly 
sensitive ELISA assays measuring matrix components and enzymes [ Hyaluronic acid (HA), 
TIMP-1 and Pro-Collagen Type III aminoterminal peptide (PIIINP)] (23). The values for each 
of these markers is combined in an algorithm which produces a discriminant ELF score. The 
score is related to the level or degree of fibrosis. The high score relates to the worse fibrosis 
stage.  
2.4 (v): Transient elastography (TE) 
 
Transient elastography (TE) is used in the Fibroscan device (Figure 8) and it measures the 
velocity of the ultrasonic sheer sound wave passing through the liver which then converts into 
a measurement of liver stiffness in kilopascals (kPa) (35). The probe of the Fibroscan device 
is positioned in an intercostal space near the right side of the liver. The procedure can be 
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performed in outpatient setting as part of bed-site clinical assessment and it is non-invasive.  
The higher readings correlate with worsening degree of liver stiffness. It can also be measured 
sequentially to monitor the progression of liver fibrosis.  
 
Figure 8: Fibroscan/Transient Elastography machine (Picture from www.intechopen.com) 
 
2.4 (vi): Liver biopsy 
 
Despite availability of non-invasive tests, liver biopsy is still the gold standard investigation in 
measuring liver fibrosis. Liver biopsy can be obtained via transcutaneous or trans-jugular 
method under radiological guidance. The trans-jugular route is preferred in patients with 
significant coagulopathy with less risk of bleeding. Liver biopsy (Figure 9-10) has been used 
to evaluate the underlying cause of liver disease, to stage disease severity in the case of viral 
hepatitis and to determine whether treatment given has been effective especially in patients 
with autoimmune hepatitis. The main disadvantage of the procedure is that the patient need to 
come into hospital as day case procedure and it is associated with significant complications 
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such as pain, bleeding, injury to internal organs such as perforation (35). In some cases, though 
biopsy will not give a desired diagnosis due to sampling error which can lead to either over-
staging or under-staging the disease (35).  
 
Figure 9: Liver biopsy procedure (http://fattyliversite.com) 
 
 
Figure 10: Histology (H&E staining) showed significant fibrosis of the liver (blue colour 
showed scarring) (36) 
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3: LIVER DISEASE MANAGEMENT 
 
3.1: Current standard management of liver cirrhosis 
 
Liver transplantation (LT) is the only curative treatment available for patients with 
decompensated cirrhosis and has a favourable 5-year survival rate (37). However, LT is not 
without risk and the major drawbacks are availability of donor organs, high operative risks and 
complications from lifelong immunosuppression (38). Due to those factors, the current 
approach is to identify patients who are at risk of developing liver cirrhosis and treat the 
underlying conditions as in alcohol management, treatment of viral hepatitis and autoimmune 
conditions to halt the progress of the disease pathogenesis.  
Despite those interventions, some patients may progress further and develop decompensated 
cirrhosis. In patients with decompensated cirrhosis, the treatment is mainly focused on 
managing the presenting clinical symptoms as well as treating the precipitating cause of those 
symptoms to develop. The common reasons for decompensation include infection, bleeding, 
constipation, drug, electrolyte disturbances, venous thromboembolism and hepatocellular 
carcinoma. The management is mainly based on treating underlying cause of liver disease as 
in abstinence of alcohol in patients with alcohol related liver disease and anti-viral therapies in 
patients with viral hepatitis. They should also be managed based on the clinical presentation.  
In patients with ascites, treatment options are diuretics, large volume paracentesis in patients 
who did not respond or tolerate diuretics and shunt insertion. The commonly performed shunt 
is TIPSS which is usually performed by an interventional radiologist. In patients with bleeding, 
the mainstay of management is endoscopy with banding for oesophageal varices and glue or 
thrombin injection for gastric varices. In patients with hepatic encephalopathy, the treatment is 
based on the underlying contributing factors. The mortality increases significantly once 
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patients develop liver decompensation and therefore they should be considered for suitability 
of liver transplantation and referred early to a liver transplant unit if deemed appropriate.  
With the increased demand of patients requiring LT, there is an urgent need to develop 
alternative treatment strategies for the treatment of decompensated chronic liver disease (CLD) 
(39) and stem cell therapies have therefore been developed in the field of liver diseases.   
3:2: Stem cells 
 
Stem cells are undifferentiated, pluripotent cells that can differentiate into multiple cell lineages 
except for primordial germ cells (40, 41). They retain the capacity to generate and renew 
themselves throughout life (42). They are divided into 4 different groups according to their 
potential for differentiation: totipotent, pluripotent, multipotent or unipotent (41).  Stem cells 
can be classified into 2 broad categories: adult stem cells and embryonic stem cells.    
 
Embryonic stem cells are pluripotent in nature and they are derived from the inner cell mass of 
the embryo which can form any cells types of the three embryonic germ layers; ectoderm, 
mesoderm or endoderm (43). There are limitations in using embryonic stem cells due to its 
potential of high immune reaction as well as the ethical concerns (43). Adult stem cells are 
multipotent cells with a limited differential potential and can form different cell types within 
the tissue although the exact mechanism of differentiation are not fully known (43). There are 
many sources of adult stem cells such as bone marrow, umbilical cord blood, fetal and adult 
liver progenitor cells, mature hepatocytes and placenta although the major populations of adult 
stem cells are obtained from bone marrow due to easy accessibility (40).  
 
Bone marrow contains at least two main populations of stem/stromal cells, haematopoietic stem 
cells (HSC) and mesenchymal stromal cells (MSC), which provide stromal support for HSC 
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(39). There had been concern about injecting unsorted bone marrow stem cells (BMSC) into 
patients with liver cirrhosis as these contain MSC which can potentially differentiate into scar 
forming myofibroblasts and worsen the underlying fibrosis (44), although more recent work 
suggests this occurs infrequently (45).  
Experimental studies of stem cell therapy in rodent models of cirrhosis have shown 
encouraging results (46-49). The first report came from Petersen and colleagues who performed 
sex mismatched bone marrow transplant in mice with liver injury and they demonstrated the 
presence of donor derived hepatocytes in the livers of transplanted mice (50). Sakaida and 
colleagues investigated the effect of bone marrow cell (BMC) tail vein infusion half way 
through an 8-week long mouse model of carbon tetrachloride (CCl4) induced liver fibrosis (11, 
48). The study found that mice the received BMC infusions had reductions in liver fibrosis as 
well as improvements in survival compared to control mice due to rise in levels of MMP-9 (11, 
48). Thomas and colleagues also demonstrated that infusion of syngeneic macrophages in a 
mouse model of CCl4-induced liver fibrosis led to a reduction in fibrosis, which was in marked 
contrast to the increase seen with unfractionated BM cells with control injured mice (11, 51). 
Due to those encouraging results, many clinical studies have been conducted in recent years to 
study for the potential benefit of stem cell therapy in liver disease (39, 52-55). Earlier studies 
were mostly feasibility and safety studies. Gordon and colleagues studied the safety and 
tolerability of injecting autologous CD34+ stem cells mobilised by granulocyte colony 
stimulating factor (GCSF) into 5 patients with liver insufficiency and showed that there were 
no complications or side effects related to the procedure (53). The study showed an 
improvement in serum bilirubin and albumin in some patients (53). In recent years, there had 
been few randomised controlled trials that studied the clinical effects of stem cells therapy in 
liver cirrhosis with variable results. Mohamadnejad and colleagues (56) conducted a 
randomised, placebo-controlled trial to evaluate the efficacy of peripheral infusion of 
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autologous bone marrow MSC in cirrhosis and the study showed that there were no beneficial 
effects in patients. Recent study by Lin and colleagues showed that peripheral infusion of 
allogenic BM-MSC is safe and significantly increased the 24-week survival in hepatitis B viral 
(HBV) related acute on chronic liver failure (ACLF) (57).  
3.2 (i): Haematopoietic stem cells (HSC) 
 
Haematopoietic stem cells (HSC) are the main stem cell population within the bone marrow 
(BM) and give rise to all mature blood lineages such as red blood cells, white blood cells and 
platelets (42) and account for approximately 0.01% of the total cells in the bone marrow (58). 
In addition to the bone marrow, HSC can be harvested from peripheral blood after mobilising 
with GCSF and umbilical cord bleed, making it possible to harvest from patients in adequate 
amounts using relatively non-invasive methods (59). In 1999, Petersen el al (50) first showed 
that hepatic cells derived from bone marrow regenerated the livers of lethally irradiated rats. A 
phase I study from Gordon et al (53) on 5 patients with decompensated liver cirrhosis proved 
that peripherally mobilised CD34+ HSC cells could be used in human and it was safe to do so. 
Since then, there had been many clinical trials on studying the effect of HSC in patients with 
liver diseases (55, 60, 61).  
 
3.2 (ii): Granulocyte colony stimulating factor (GCSF) 
 
Granulocyte-colony stimulating factor (GCSF), a protein containing 175 amino acids, was 
routinely used in haematological malignancies for BMC transplantation purposes and had 
potent mobilisation capacity of haematopoietic stem cells in donors and chronic haematological 
patients (62, 63). The effects of GCSF are not limited to the mobilisation of bone marrow 
derived cells but also due to autocrine and paracrine effects within the liver, promoting and 
enhancing the oval cell reaction (64). This synergistic effect of BMSC and oval cells might be 
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responsible for improvement of liver function post GCSF therapy (64). GCSF also improves 
neutrophil activity which can improve the severe immunological dysfunction that characterises 
the pathophysiology behind ACLF, prevent sepsis and reduce mortality (64).  
 
GCSF treatment significantly improved survival and liver histology in chemically injured mice, 
predominantly by promoting endogenous repair mechanisms as per the study from Yannaki 
and colleagues (65). They studied the possibility that GCSF mobilised bone marrow cells could 
home to the injured liver of mice model and promote tissue repair (65). The study showed that 
GCSF administration increased BM-derived hepatocytes that caused acceleration in the 
regeneration process with significant improvement in survival (65). Another study showed that 
5 days treated with GCSF decreased the hepatic inflammation and improved survival in acute 
hepatic injury rat model (66).  
 
Those studies led to clinical studies and GCSF has also been used in patients with both chronic 
liver cirrhosis and ACLF with some promising outcomes (52, 67, 68). Gaia and colleagues 
studied the effect of GCSF in 8 patients with liver cirrhosis and showed that GCSF was well 
tolerated with no serious adverse events (68). Recent study from Singh and colleagues showed 
that GCSF administration improved CPS, MELD score and 90-day survival rate in patients 
with severe alcoholic hepatitis (69). The differentiation of bone marrow stem cells had been 




Figure 11: Types of bone marrow stem cells in human  
 
3.3 (iii): Methods for stem cell therapy 
 
Stem cells can be administered in different ways: via hepatic artery infusion (70), intrahepatic 
injection (38), portal vein injection (54), intra-splenic injection (38) or peripheral infusion (71, 
72). Each route has their own benefits and risks associated with it and the ideal way to deliver 
cell therapy should be based on the following factors: easy to perform, minimally invasive to 




4: MECHANISTIC ACTION OF HAEMATOPOIETIC STEM CELL 
THERAPY IN MICE MODEL OF LIVER FIBROSIS 
4.1: Rationale behind animal work 
 
4.1 (i): My role within this project 
 
My lab-based project was an extension of previous project completed by Dr Andrew King (PhD 
fellow). The frozen mouse tissue samples and fixed paraffin slides were handed over to me to 
complete the project. During my research time, I learnt to perform immuno-histochemistry 
staining and analysis as well as techniques in performing RNA extraction, cDNA synthesis, 
running qPCR panel and interpretation of the results. 
4.2: Overview of previous completed data  
 
The results of this study had been published and I was one of the author (74) and the section 
below are from that published manuscript as well as from Dr King’s PhD Thesis.  
4.2 (i): Ethic approval for the animal work  
 
This section was reproduced from Dr Andrew King PhD thesis 
All animal experiments performed were conducted in accordance with the Animals (Scientific 
Procedures) Act 1986 under a Project Licence (PPL 40/3201) (74).  Approval from the 
University of Birmingham Ethics Committee was obtained. All animals were housed in an 
approved animal facility (Biomedical Services Unit, University of Birmingham) under 
conditions of 12-hour light/dark cycles and with unlimited access to food and water (74). 
C57/Bl6 mice were supplied directly to the Biomedical Services Unit by Harlan UK and used 
for cell isolation at 6-8 weeks of age and for experimental procedures at 8 weeks of age (74). 
BoyJ (B6.SJL-Ptprca Pep3b/BoyJ) mice were supplied from a colony maintained in the 
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Biomedical Services Unit and used for experimental procedures at 8 weeks of age (74). At the 
completion of experimental procedures mice were euthanased under terminal inhalational 
anaesthesia (3% Isoflurane) allowing blood sampling via cardiac puncture to be performed 
prior to death. Mice used for cell isolation were euthanased using cervical dislocation as 
approved under Schedule1 of the Animals (Scientific Procedures) Act. 
4.2 (ii): Results generated by previous researcher 
 
This section was reproduced from Dr Andrew King PhD thesis 
Dr King used the carbon tetrachloride model of liver injury to investigate the effect of chronic 
liver injury on c-kit+ sca1+ lin- (KSL) HSC mobilisation and recruitment to the liver. Carbon 
tetrachloride was used in age and sex matched C57/Bl6 mice at a dose of 1mg/kg body weight 
(diluted 1:4 in mineral oil vehicle) and administered to mice by intra peritoneal injection and 
control mice received twice weekly intraperitoneal injections of mineral oil.  After 8 weeks of 
treatment, a significant chronic liver injury developed. Mice were then sacrificed, and bone 
marrow, peripheral blood and liver obtained. Significantly higher numbers of HSC determined 
by KSL surface phenotype were found in the livers (Injury 1163 +/- 173 KSL cells per liver vs 
Control 258.5+/-22.2 KSL cells per liver, p<0.01) and peripheral blood (Injury 0.397+/-0.055 
KSL cells per μl blood vs Control 0.0674+/-0.011 KSL cells per μl blood, p<0.001) of mice 
with liver injury compared with control mice (Figure 12 A, B) (74). The numbers of HSC 
within the bone marrow remained constant (Injury 2323+/-48.9 KSL cells per femur vs Control 
2327+/-64.3 KSL cells per femur, p=not significant) (Figure 12 C) (74).  
 
BoyJ mice were allocated randomly to either treated or control group (n=8 in each group). KSL 
cells from donor mice C57/BL6 mice were injected via tail vein into the mice in the treated 
group at the start of weeks 7, 8 and 9 (74) (Figure 13). Quantitative morphometric analysis of 
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fibrosis in the liver using picrosirius red staining (Figure 14 A, B) revealed significantly lower 
levels of collagen deposition within the liver with a 49.7% reduction in staining in the KSL cell 
treatment group compared with controls (KSL 2.207+/- 0.119 % staining area vs Control 
4.388+/-0.27 %staining area, p<0.0001) (74). Serum albumin levels were measured as a marker 
of liver synthetic function and in the treatment group, the levels were significantly higher than 




Figure 12 (A-C): The numbers of haematopoietic stem cells (HSC) determined by c-kit+ sca1+ 
lin- (KSL) surface phenotype were found in the peripheral blood, livers and bone marrow (74), 
**p<0.01 ***p<0.001 (two tailed, unpaired students t-test) (Reproduced from Dr Andrew 




Figure 13: Time frame of c-kit+ sca1+ lin- (KSL) cells injection in carbon tetrachloride (CCL4) 
model of mouse liver fibrosis (Reproduced from Dr Andrew King’s PhD Thesis and (74))  
 
Figure 14 (A-C): Comparison between c-kit+ sca1+ lin- (KSL) treated mice and control mice 
(A, B: Percentage Sirius red staining quantification, C: Albumin level) (74), **p<0.01 
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***p<0.001(two tailed, unpaired students t-test) (Reproduced from Dr Andrew King’s PhD 
Thesis) 
4.3: Hypothesis of the current project 
 
 
In chronic liver injury, there was an increased accumulation/turnover of ECM which is 
predominantly driven by hepatic stellate cells (75). MMPs and TIMPs are the main regulators 
of ECM turnover in liver fibrosis (75) and MMP activities are under close control by TIMPs 
(76). The roles of MMPs and TIMPs in hepatic fibrosis have been well studied in CCL4 
induced mouse liver injury with increased expression of several MMPs especially MMP-1, 8, 
9 and 1 (75, 76).   
 
The rationale behind the project was to understand the nature of MMP expression in the model 
of mouse liver injury that received purified KSL cells infusion. MMP9 and MMP13 expression 
was studied in the livers of control and KSL cells treated mice.  The reason behind choosing 
these MMPs was that both MMPs are involved in remodelling of ECM after liver injury as 
mentioned above due to their fibrinolytic nature. Previous study also showed that mice 
undergoing CCl4-induced injury had macrophage-rich infiltrates and a blunted oval cell 
response (77) with stem cells therapy considered to be able to increase the oval cells response. 
To identify oval cell reactions, immune-histochemical staining for pan-cytokeratin (Pan-CK) 
and Sry/sex determining region Y-box 9 (Sox-9) was performed. 
 
4.4: Immunohistochemistry Staining  
 
4.4 (i): Methodology 
 
Staining of formalin fixed paraffin embedded sections started with de-waxing the sections 
through series of graded solutions: washed twice with xylene, washed twice with alcohol and 
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finally washed in deionised water. Sections were then placed in plastic humidifier chamber and 
150 µl of readymade Peroxidase-blocking solution, DAKO real (S2023) was added to each 
section and then incubated on rocker for 40 minutes to block endogenous peroxidase activity, 
followed by washing two times in TBS (Tris buffered saline) and 0.1% Tween-20 (TBS-T) for 
5 minutes. Antigen retrieval was performed using the following steps: mixing 10 ml of high 
pH antigen unmasking solution (H-3301, Vector Lab) with 990 ml of distilled tap water in a 
plastic container and heated at high power to 95-100◦C for 5 minutes in a microwave oven; the 
sections were then immersed and heated for further 15 minutes at full power The sections were 
allowed to cool slowly to room temperature and then washed twice in TBS-T. Nonspecific 
binding of antibodies to the sections was blocked by incubating the sections for 30 minutes 
with 150 ul of Casein buffer solution (x10) which was diluted to 1x with distilled water prior 
to use. The casein solution was tipped off the slide and the primary antibody was added diluted 
in TBS to the appropriate concentration (Table 5) and incubated for 1 hour at room temperature 
in a humidified chamber on a rocker. The sections were then washed two times in TBS-T 
followed by addition of the relevant horse radish peroxidise conjugated secondary antibody 
(ImmPRESS Peroxidase Anti-Rabbit IgG or ImmPRESS Peroxidase Anti-Rat (Mouse 
Adsorbed) IgG, Vector Labs) for 30 minutes, followed by washing in TBS-T twice. 
Diaminobenzidine (DAB) was used as the peroxidase substrate and DAB substrate was 
prepared by adding 1 drop of DAB to 1 ml of substrate buffer and mixed gently. The sections 
were incubated with ImmPACT DAB reagent (VectorLabs) until the tissue turned brown 
(varied between 20 second to 2 minutes). Sections were then washed once in water for 5 
minutes and counterstained with Mayer’s haematoxylin for 20 seconds, washed again in tap 
water for 2 minutes and 30 seconds and afterwards, run under warm tap water for further 2 
minutes and 30 seconds.  The sections were dehydrated through graded alcohols /xylene 





Table 5: Antibodies used in immunohistochemistry staining 
Antibody Origin Target Isotype Supplier Dilution Antigen 
Retrieval 









Rabbit Mouse Polyclonal DAKO  1: 500 High pH 
(VectorLab) 
 
4.4 (ii): Immuno-staining analysis  
 
The number of individual stained cells in 6 random, non-overlapping fields of view (x100) was 
counted using Image J software. The data were then analysed with Prism GraphPad software 
(version 6) using non-parametric Wilcoxon test. P valve of <0.05 was considered as statistically 
significant.  
4.4 (iii): Immuno-staining results 
 
Quantification of hepatic oval cell numbers, as indicated by pan-cytokeratin staining in CCL4 
injured mice (control) and KSL-cells treated mice had higher percentage of pan CK positive 
staining in tissue compared to control mice (p<0.01) (Figure 15) (74).  
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Figure 15: Comparison in qualitative analysis of Pan-CK staining between control and c-kit+ 
sca1+ lin- (KSL) treated mice (74), **p<0.01 (two tailed, unpaired students t-test) 
In the adult organ, Sox9 marks the precursor cell population during physiological cell 
replacement and/or during the regenerative process after injury (78). Sox9 expression had been 
detected in cytokeratin 7–positive bile duct cells of the liver, including the canals of Hering, 
but not in hepatocytes (78).  When damage occurs in the liver, a Sox9-dependent process causes 
HSCs to become activated through TGF-β signaling in type 1 collagen production (79). In the 
study, KSL administration did not result in a difference between the two groups in Sox-9 
staining (p=0.31) (Figure 16). In addition, immune staining for both MMP-9 and MMP-13 
showed an increased expression of both in KSL treated groups (Figure 17) (74).  
    





Figure 17: Comparison of MMP 9 and 13 staining in control and c-kit+ sca1+ lin- KSL treated 
mice (74), *p<0.05, **p<0.01 (two tailed, unpaired students t-test) 
 
4.5: Quantitative polymerase chain reaction (qPCR)  
 
4.5 (i): Methodology  
 
RNA extraction: RNA Isolation was performed using the RNeasy Mini Kit (Qiagen). For RNA 
isolation from tissue, approximately 25 to 30mg of the relevant tissue was placed in a 
GentleMACS M tube (Miltenyi Biotec) together with 600μl of RLT buffer supplemented with 
10 μl/ml 2-mercaptoethanol (Sigma). Samples were processed on the Miltenyi GentleMACS 
processor using program RNA.01_01 producing a tissue homogenate ready for RNA extraction. 
Tissue lysate was transferred to Eppendorf tube and centrifuged for 3 minutes at 1300 RPM. 
600 ul of 50% Ethanol was added to the supernatant and immediately mixed by pipetting and 
this mixture was transferred to a RNeasy Spin Column and centrifuged at >10,000 rpm for 15 
seconds. The column flow through was discarded and 350μl RW1 buffer was added to the spin 
column and centrifuged at >10,000 rpm for 15 seconds.  80μl of RNase free DNase solution 
(10 ul of DNAase stock solution to 70 ul of Buffer RDD) was then added directly to the spin 
column membrane and left to incubate for 15 minutes at room temperature. A further 350μl 
RW1 buffer was added to wash the spin column and centrifuged at >10,000 rpm for 15 seconds. 
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500μl RPE buffer was twice added to the spin column and centrifuged at >10,000 rpm firstly 
for 15 seconds then for 2 minutes. The columns were transferred to a new collection tube and 
centrifuged for 1 minute to allow solvent to evaporate from the membrane.  After this, 50μl of 
RNase free water was added to the membrane and centrifuged at >10,000 rpm for 1 minute to 
elute the RNA and this step was repeated.  All RNA samples were assessed for quantity and 
purity of RNA using a Nanodrop-100 spectrophotometer. Samples were used for cDNA 
synthesis if the ratio of absorbance at 260nm (A260) to absorbance at 280nm (A280) was 
between 1.8 and 2.0, indicating low levels of genomic DNA contamination. RNA samples were 
aliquoted and stored at -80◦C pending use in further applications. 
 
cDNA Synthesis: Each cDNA synthesis reaction was run in a thin walled PCR tube and 
consisted of 4.5μg RNA template added to 0.5 ul Random primers (Promega) and 1ul of dNTP 
Mix (100mm, 500 ul, Bioline). The mixture was made up to total volume on 12 ul with RNase 
DNAse free water (Qiagen).  The reaction mix was incubated in a thermal cycler at 65◦C for 5 
minutes and after that, the mixture was chilled on ice quickly. 5x First Strand Buffer, 0.1M 
DTT and Superscript IIRT was from Superscript II reverse transcriptase 10,000 U Invitrogen 
(Life Technologies) 4 ul of 5x First Stand Buffer, 2 ul of 0.1 M DTT and 1 ul of RNase DNase 
free water (Qiagen) were added to each tube. They were mixed gently and incubated at 25◦C 
for 2 minutes. 1 ul of Superscript II RT was added to each mixture and mixed gently, followed 
by incubation in a thermal cycler at 25◦C for 10 minutes, 42◦C for 50 minutes and finally the 
RI was inactivated by incubation at 70◦C for 15 minutes. The reaction was then cooled to 10°C 
and either used immediately for further applications or stored at -80◦C. 
 
Quantitative PCR: Polymerase chain reaction is a process by which samples of DNA undergo 
geometric amplification, yielding many copies of the original DNA sequence. The reaction is 
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catalysed by a heat stable DNA polymerase (Taq polymerase). Taqman gene expression assays 
were used in this work. Taqman fluorescent probes have the reporter dye FAM at the 5’ end 
and the quencher MGB at the 3’ end. The intact probes do not fluoresce as the reporter and 
quencher are in close proximity. As the reaction mixture cools during each cycle after the 
denaturation step the probe is able to hybridise with its target sequence. During the elongation 
step which follows the polymerase encounters the bound probe and the 5’ nuclease activity of 
the enzyme separates the reporter from the quencher, thus rendering the reporter fluorescent. 
The free reporter molecules are excited by the detection instrument which detects emission of 
fluorescence. The amount of fluorescence is proportional to the number of copies of the target 
sequence. 
 
Individual Taqman Gene Expression Assays used in this work are listed in Table 6. Each of 
these assays were inventoried and validated by the manufacturer. For each experiment, PCR 
mixture was made according to the following ratio: 800 ul of Taqman 2x Universal PCR Master 
Mix (Applied Biosystems), 625 ul of RNase DNAase free water (Qiagen) and either 40 ul of 
target Taqman Gene Expression Assay or GAPDH (Table 6).  Reactions were performed on a 
96 well PCR plate (Life Technologies) and 14 ul of PCR mixture and 1 ul of cDNA sample 
was added to each well of the plate to make up the total volume of 15 ul. PCR was performed 
using LightCycler 480 instrument and the programme used consisted of polymerase activation 
at 95°C for 10 minutes followed by 40 cycles of denaturing (95°C for 10 seconds) and 
annealing (60°C for 30 seconds and 72°C for 1 second) and cooling (40° C for 10 seconds).  
 
The fluorescence of each reaction was recorded at the end of each cycle. Each reaction was 
performed in triplicate and control reactions which did not contain any cDNA template were 
also included. Cycle threshold (cT) values were obtained and the difference between the 
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reference and target gene calculated (ΔcT = cT target – cT reference). Relative differences 
between samples was expressed using the 2-ΔΔCT, where ΔΔcT = ΔcT sample1 – ΔcT 
sample2. The use of the ΔΔcT method to determine relative differences between samples under 
varying conditions is reliant upon there being no differences in the amplification efficiencies 
of the target and reference genes. The analysis was performed automatically on the software of 
LightCycler 480 which was then crossed checked with manual calculation.  
 
Table 6: Gene expression assay used for PCR 
Target (Murine) Gene Expression Assay 
Matrix Metalloproteinase 2 Mm00439498_m1 
Matrix Metalloproteinase 8 Mm00439509_m1 
Matrix Metalloproteinase 9 Mm00442991_m1 
Matrix Metalloproteinase 12 Mm00500554_m1 
Matrix Metalloproteinase 13 Mm00439491_m1 
Inducible Nitric Oxide Synthase (iNOS) or NOS 2 Mm00440502_m1 
Arginase-1 Mm00475988_m1 
Glyceraldehyde 3-phosphate Dehydrogenase Mm99999915_ g 1 
 
4.5 (ii): Results for qPCR  
 
The results showed that expression of MMP 2, 8, 12 and were similar between the two groups 
(Figure 18). MMP 9 was significantly higher in KSL treated group compared to control group 




Figure 18: Quantitative polymerase chain reaction (qPCR) results of MMP2, MMP 8, MMP 9, 
MMP 12, MMP 13, Arg 1/NOS-2 expression ratio (74) * P<0.05 (two tailed, unpaired students 
t-test) 
4.6: Discussion  
 
Bone marrow stem cell therapy in liver disease is emerging but there is still uncertainty in 
relation to their efficacy as well as the type of stem cells required (74). In this study, we showed 
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that repeated injections of purified haematopoietic stem cells resulted in marked resolution of 
fibrosis by promoting the recruitment of endogenous macrophages and neutrophils with 
associated increases in MMP 9 and 13 expressions in KSL treated mice (74). We also examined 
the effect of oval cell response in KSL treated mice by staining the liver tissues with pan-CK 
and Sox-9. CK are expressed in epithelial cells and their functions include providing 
mechanical strength to the epithelial cells and also transport membrane proteins (80). 
Breakdown of CK by caspases plays a role in apoptotic process (80). CK7 and CK19 are 
strongly expressed in interlobular bile ducts, intraportal and intralobular bile ductules, the 
biliary epithelial cells and hepatic progenitor cells (80). Our study showed that there was a 
significant increase in number of pan-CK positive cells in the KSL treated group but not for 
Sox-9 staining. Both are used as markers of oval cell response to injury but with stem cell 
treatment, the positive finding was only seen in pan-CK staining. Tarlow et al mentioned that 
Sox9+ ductal proliferation makes only a minor contribution to parenchymal regeneration in 
liver injuries (81). It is possible that Sox 9 staining did not showed any positive response since 
Sox 9+ cells contribute only a minor response towards the hepatic regeneration process. KSL 
treated mice had significantly higher levels of MMP-9 and 12 compared to control mice which 
potentially increased the process of breaking down fibrosis in ECM remodelling.  
For qPCR, there was an increased expression of MMP-9 in KSL treated mice compared to the 
control group but not in any other forms of MMPs. We examined the macrophage subsets in 
the livers of KSL treated mice since previous studies mentioned that bone marrow cells can 
differentiate into myofibroblast like cells and worsen the fibrosis process. There was no 
difference in the proportion of individual macrophage subsets (Arg-1 and Nos-2) from qPCR 
analysis although there was a reduction of Arg-1/Nos-2 ratio compared to the control group 
indication that there was no obvious increased risk seen in KSL treated mice. This change in 
ratio may be indicative of a change towards an anti-fibrotic milieu. 
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In summary, this work showed that repeated infusions of HSCs in CCL4 injured mice were 
safe and associated with an antifibrotic effect as supported by increases in the expression of 
MMP9 and 13 as well as an improvement in oval cell response as evidence by increased pan-
CK staining in KSL treated mice. Due to prior data we designed and conducted a clinical trial 
to examine the effect of repeated haematopoietic stem cell infusions in patients with chronic 




5: CLINICAL TRIAL 
 
5.1: Role within the clinical trial 
 
During the two and a half years of research fellowship, my main aim was to recruit patients to 
complete the clinical trial. The trial was initially started in 2009 and the first draft of the 
protocol was completed by previous research fellow, Dr King. I was then involved in the 
process of amending the clinical trial protocol.  
My responsibilities that within this trial include:  
1) Involved in the process of amending clinical trial protocol (final amendment was made 
on 5th March 2015) 
2) Weekly screening of patients’ electronic clinical records (clinical letters, imagining and 
blood tests) and identifying suitability 
3) Contacting suitable patients either in person at clinic or via telephone conversation to 
explain about the clinical trial.  
4) Keeping track of patients that had been approached and contacting them in a timely 
manner to recruit.  
5) Contacting other hospitals within the West Midlands region to ensure that patients from 
secondary non-specialised hospitals were involved in the trial.  
6) Getting a written consent from the patients, followed by detailed clinical assessments 
(clinical examination, review of blood tests/ imaging and electrocardiogram) 
7) Assessing patients’ clinical conditions regularly during their treatment and follow-up 
visits throughout.  
8) Involving in addressing patients’ queries and concerns throughout the study period. 
9) Working together with clinical research team and helping them with data cleaning 
especially in documentation of adverse events.  
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When I first started, 37 patients had already been recruited into the trial and the recruitment 
was completed in March 2015, 6 months prior to completing my post graduate study.  
5.2: Clinical trial methodology 
The manuscript for the clinical trial protocol had been published (I was an author) and the 
following chapters were from the published manuscript (72).  
5.2 (i): Research aim 
 
The aim of the study was to access the safety and efficacy of GCSF and haematopoietic stem 
cells (HSC) infusions in patients with liver cirrhosis (72, 82).   
5.2 (ii): Methods and analysis 
 
The REALISTIC trial was a multicentre, open-label phase II randomised controlled trial of two 
different therapies: 1) administration of GCSF alone and 2) administration of GCSF, followed 
by isolation of CD133+ HSC and repeated infusion of those cells. Those therapies are 
compared with standard management of compensated cirrhosis according to local, national and 
international guidelines (72).  
5.2 (iii): Trial organisation 
 
The trial was an investigator led and designed trial, co-ordinated by the Liver Research group 
within the Cancer Research Clinical Trials Unit at the University of Birmingham (72). The 
University of Birmingham was the trial sponsor and the trial was funded by NIHR (National 
Institute for Health Research) Biomedical Research Unit for Liver Disease, Birmingham and 
the Sir Jules Thorn Trust (72). The trial was run at three sites in the United Kingdom 
(Birmingham, Edinburgh and Nottingham) and recruitment began in May 2010 (72).  
The trail was registered at Current Controlled Trials (http://www. Controlled-trials.com) on 18 
November 2009 (ISRCTN number 91288089, EuDRACT number 2009-010335-41) (72). The 
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procurement, processing, storage and distribution of the Autologous CD133+ HSC were 
performed in accordance with Tissue Quality and Safety Regulations by establishments 
holding Human Tissue Authority licenses (72). 
5.2 (iv): Inclusion and exclusion criteria 
 
The details of the inclusion and exclusion criteria are listed in table 7 and 8.  
Table 7: Inclusion criteria of the clinical trial (72, 82) 
Inclusion criteria Details 
Age 18 to 75 years 
MELD at randomisation 11.0 and 15.5 
Aetiology of liver diseases (one or more of) o Alcohol related liver disease: 
features (clinical, biochemical, 
histological or radiological) of 
chronic liver disease with a 
compatible history of alcohol excess 
>80g/day), in the absence of other 
causes of chronic liver disease.  
o Hepatitis C with positive HCV 
antibody and who are not currently 
on antiviral treatment 
o Hepatitis B with positive HBsAg and 
Anti-HBc and who are on established 
antiviral therapy with adequate viral 
suppression.  
o Primary biliary cholangitis with 2 
out of: cholestatic LFTs, positive 
AMA (>1:40), compatible 
histology. If already receiving 
ursodeoxycholic acid, the treatment 
must be established on current dose 
for >3 months prior to enrolment 
o Genetic haemochromatosis with 
diagnosis made on basis of 
compatible biochemistry 
(transferrin sat >60%, ferritin 
>400), genotype (homozygous 
C282Y or H63D, compound 
heterozygote) or Histology 
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Inclusion criteria Details 
o Cryptogenic cirrhosis 
Diagnosis of cirrhosis un-
attributable to any other cause 
o Non-alcoholic fatty liver disease 
(NAFLD) with diagnosis by either 
the presence of histological 
evidence of steatosis in the absence 
of other liver diseases or 
radiological evidence compatible 
with NAFLD (e.g. Fatty infiltration 
of liver) and one or more risk 
factors (e.g., elevated BMI, T2DM, 
hypertriglyceridemia, hypertension) 
and the absence of significant 
alcohol consumption (<20 g/day) 
and no evidence of other causes of 
chronic liver disease 
o α-1 anti-trypsin deficiency with 
diagnosis based on compatible 
genetic, phenotypic or histological 
testing 
 
Cirrhosis as defined as o previous liver biopsy confirming 
histological features of cirrhosis 
o Fibroscan >16 kPa 
o Clinical and radiological features 
correlate with diagnosis of cirrhosis 
(as per opinion of investigator) 







Table 8: Exclusion criteria of the clinical trial (72) 
Exclusion criteria Details 
General o Refusal or inability to give 
informed consent 
o Any situation that in the 
Investigator's opinion may interfere 
with optimal study participation 
such as alcohol or drug abuse, 
domicile too distant from study site, 
potential non-compliance or 
inability to co-operate 
o Participation in any clinical study of 
an investigational agent within 30 
days of randomisation 
o The presence of clinically relevant 
cardiovascular, pulmonary, 
gastrointestinal, renal, metabolic, 
haematological, neurological, 
psychiatric, systemic, ocular, 
gynaecological or any acute 
infectious disease or signs of acute 
illness that in the opinion of the 
investigator might compromise the 
patient's safe participation in the 
study 
o Presence or history of cancer within 
past 5 years with exception of 
adequately treated localised basal 
cell carcinoma of the skin, in situ 
cervical cancer or solid malignancy 
surgically excised in total without 
recurrence for 5 years 
 
Pregnancy or breast feeding Women of childbearing potential and men 
who have partners of childbearing potential 
who are not willing to practise effective 
contraception for the duration of the study 
and for 12 months (females) and 6 months 
(males) after the last study drug 
administration 
Liver specific o Alcohol ingestion >21 units/week in 
male and >14 units/week in female 
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Exclusion criteria Details 
o Aetiology of chronic liver disease 
(not listed in the inclusion criteria) 
o Ascites—unless minimal and well 
controlled with no changes to 
diuretic therapy in the last 3 months 
o Encephalopathy—current or 
requiring hospitalisation in last 3 
months 
o Portal hypertensive bleeding—
active or requiring hospitalisation in 
past 3 months 
o Hepatocellular carcinoma—current 
or previous 
o Liver transplantation—previous or 
on waiting list 
 
Granulocyte colony stimulating factor 
(GCSF) related 
Recent history of pulmonary infiltrates or 
pneumonia: patients should have completely 
recovered from any previous episodes, both 
clinically and radiologically 
 
5.2 (v): Screening  
 
Patients were identified and recruited at the participating trial site and gave written informed 
consent at the beginning of the screening visit prior to undergoing any tests or procedures 
needed to assess their eligibility (72). Patient’s eligibility for the study was determined by 
clinical assessment including a full medical history followed by thorough clinical examination, 
blood tests, complete liver aetiology screen if not previously performed, 12 lead E.C.G (Electro 
cardiogram), chest X-ray, abdominal ultrasound scan, liver stiffness evaluation by Fibroscan, 
baseline chronic liver disease questionnaire (CLDQ) and urine pregnancy tests for female 
patients of child bearing age (72). As required by National Health Service (NHS) Blood and 
Transplant Standard Operating Procedures, prior to processing and storage of cellular products, 
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patients were tested for viral infections: viral hepatitis B and C, human Immunodeficiency virus 
(HIV), human T-cell lymphotrophic virus (HTLV)-1 and 2 and syphilis (72).  
5.2 (vi): Randomisation 
 
Centre-delegated staff telephoned randomisation officers at the Cancer Research UK Clinical 
Trials Unit (Birmingham, UK), who used a computer-generated, centrally administered 
procedure to randomly assign eligible patients (1:1:1) to one of three treatment arms (82). 
Randomisation was based on a minimisation algorithm (prepared and validated by the CRCTU 
programming and statistical team) and patients were also stratified by (i) trial site (ii) aetiology 
of disease (82). The patient was then allocated a unique patient trial number and scheduled for 
treatment and follow up visits (82). The local site staff could not pre-determine treatment 
allocation (82). Since the study was an open label, both clinicians and local site staff including 
the patient were aware of which treatment had been allocated (82). After 
randomisation/treatment and depending on allocated arm, patients returned for study visits at 
days 30, 60, 90, 180 and 360 (end of study) (82). 
5.2 (vii): Study treatment 
 
During the trial period, all patients received standard medical management of underlying liver 
cirrhosis, which may include disease specific treatment (antiviral treatment for hepatitis B, 
ursodeoxycholic acid for primary biliary cholangitis) and treatments for the complications of 
cirrhosis (72). Concomitant medications were used at the discretion of the site investigator with 
the exception of the introduction of antiviral therapy for chronic HCV infection, changes to 
medications for chronic HBV infection, the introduction of UDCA for PBC and participation 
in another clinical trial of an investigational product (72).  
Patients were randomised into:  
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Group 1: Patients randomised to group 1 received standard medical therapy (control group).  
Group 2: Patients randomised to group 2 received GCSF (Lenograstim) therapy without 
CD133+ HSC infusions. The treatment began within 7 days of randomisation and patients 
received subcutaneous (SC) injection of GCSF 15 ug/kg of body weight for 5 days, in addition 
to their standard medical therapy.  
Group 3: Patients randomised to group 3 received SC injection of GCSF 15ug/kg for 5 days 
within 7 days of randomisation, in addition to their standard medical treatment. On the fifth 
day of GCSF treatment, leukapharesis was performed according to the standard operating 
procedure in place at each site and CD133+ cells were collected. If there was insufficient 
number of CD133+ cells, a second leukapharesis was performed on day 6. The cells were 
reinfused on days 6, at 1 month and 2 months from randomisation. The randomisation was 
illustrated in Figure 19.  
 




CD133+ HSC were isolated from the harvested peripheral blood mononuclear cells (MNC) 
under aseptic conditions within clean room facilities in accordance with good manufacturing 
practice regulations (Medicines and Healthcare Products Regulatory Agency, MHRS/HTA, 
UK) (72). CD133+ HSC are isolated through immunomagnetic positive selection using super 
paramagnetic iron dextran particles directly conjugated to CD133 antibodies (72). This is 
performed in close, sterile system providing clinical grade enrichment (CliniMACS Plus, 
Miltenyi Biotec, Germany) (72). The CliniMACS system has been shown to provide CD133+ 
cells at up to 97% high purity and yields up to 81% (82-84) with passive depletion of unwanted 
cells. The CliniMACS Plus instrument is CE-marked for clinical use in Europe (72).  
Isolated CD133+ HSC were aliquoted in three portions in the required quantities, one portion 
is available for immediate re-infusion and other two portions were cryopreserved according to 
site protocols for later reinfusion at day 30 and day 60 from randomisation (72). The dose of 
CD133+ HSC re-infused was 0.2 x 106 cells/kg for each of the three infusions and hence, the 
minimum cells required for the collection was 0.6 x 106 cells/kg (72). If there were insufficient 
cells for three doses, the cells were allocated preferentially to the first, then second and third 
dose (72).  
5.2 (viii): Primary outcomes 
 
The primary objective was to demonstrate an improvement in liver function and reduction in 
liver fibrosis in patients receiving therapies compared with those receiving standard medical 
therapies (72). This objective was measured by the change in MELD score, also known as delta 
MELD, at day 90 from the day of randomisation, noted as day 1 (72). The trend of treatment 
activity by incorporating MELD measured at baseline and days 30, 60 and 90 was also included 
as co-primary 2 outcomes (72). The protocol was updated in March 2015 to include co-primary 
2 (72). Co-primary 2 measured the effect of treatment on the change in MELD that was also 
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explored through linear mixed-effects models to find a most appropriate parsimonious model 
which incorporated measurements taken at baseline and at days 30, 60 and 90. Random effects 
were assigned at the patient level (82). 
5.2 (ix): Secondary outcomes 
 
The secondary objectives were treatment related adverse events, liver fibrosis, disease related 
quality of life, liver related clinical events and transplant free survival. Liver fibrosis was 
measure by non-invasive methods and those included 1) Fibroscan TM, Echosens, France and 
ELF test (72). ELF was CE marked and approved for use in research and now in clinical 
practice (72). The serum ELF samples were sent to Southampton for analysis (72). Fibroscan 
was performed at randomisation (day 1), and repeated at day 90, day 180 and day 360 (72). 
Blood tests for ELF test were collected at randomisation/day 1, day 30, day 90, day 180 and 
day 360 (72).  
Disease related quality of life was measured by “Chronic Liver Disease Questionnaire 
(CLDQ)” (72). In CLDQ, there were 29 items that was divided into 6 quality of life domains 
(abdominal symptoms, fatigue, systemic symptoms, activity, emotional function and worry) 
(72). These items were ranked on a 1 to 7 scale, providing a range of scores from 29 (worse 
quality of life) to highest 203 (best quality of life) (72). Patient completed CLDQ questionnaire 
at randomisation (day 1), day 90, day 180 and day 360 (72). The example of CLDQ 
questionnaire used in this study was shown in appendix 1. UKELD score was also calculated 
at randomisation (day 1), day 90, day 180 and day 160 (72). 
Patients were followed up for 12 months from the day of randomisation for survival (72). 
During the follow up, treatment related adverse events and liver related clinical events were 
monitored and recorded at each visit and any unscheduled visits (72). The liver related clinical 
events recorded were 1) Newly developed clinical significant ascites or worsening of 
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established ascites (confirmed radiologically) 2) Encephalopathy that require introduction of 
treatment or hospitalisation 3) Portal hypertensive bleeding (confirmed at endoscopic 
examination) 4) Spontaneous bacterial peritonitis (confirmed on ascitic fluid sample with 
polymorphonuclear cell count of >250cm3 5) Development of hepato-renal syndrome 6) 
Listing for liver transplantation 7) Diagnosis of liver cancer  and 8) Death.  
5.2 (x): Recruitment 
 
The trail recruitment was started on 18th May 2010 and was completed on 26th February 2015.  








The clinical trial manuscript has now been published (I was one of the author) and the following 
chapters are from the published manuscript (82).  
6.2: Results 
 
6.2 (i): Statistical analysis  
 
Statistical analysis was performed by trial statistician and consent was obtained for this 
section to be used.  
The sample size calculation was based on the change in MELD score from baseline to 90 days’ 
post-randomisation (82). With pooled standard deviation assumed in this controlled setting to 
be 1.25, this trial aimed to detect a standardised effect size of at least 0.8 between treatment 
arms and control, equating to a 1-point reduction in MELD (82). Error rates based on two sided 
α=0.05 (α=0.10 split equally between the two hypotheses) and 80% power, required 
recruitment of 27 patients into each arm (72, 82).  
The trial was designed as a three-armed study with one control arm and powered to compare 
each treatment to control with respect to co-primary 1 but was not powered to detect differences 
between the two treatment arms (82). Analysis of primary outcome measure: the hypothesis 
was designed to assess activity and as such all analyses were carried out in the modified 
intention to treat (mITT) population. Modified intention to treat (mITT) population included 
participants who were 1) protocol violator 2) ineligible participants 3) participants who 
received at least 1 day of GCSF at 15ug/kg in G2,4) participants who received one infusion of 




Co-primary 1: Change in MELD from baseline to day 90 was calculated for each participant 
and arms 1 and 2 were compared to control using the non-parametric two-sample Wilcoxon 
test. Exploratory linear regression models, with transformed MELD where required, were fitted 
to enable adjustment of co-primary 1 estimates (82). 
Co-primary 2: The effect of treatment on the change in MELD was also explored through linear 
mixed-effects models for modelling approach to find a most appropriate parsimonious model 
which incorporated measurements taken at baseline and at days 30, 60 and 90. Random effects 
were assigned at the patient level (82).  
Co-primary 1 is conditional on availability of day 90 MELD measure, whereas co-primary 2 is 
not (82).  
Sensitivity analyses included adjustment of model- based analyses for known prognosticators, 
such as alcohol and aetiology, minimisation factors and for differences observed at baseline 
(82). UKELD was analysed as per co-primary 1 and 2, and CLDQ responses were assessed 
through area-under-curve analyses with a set of varied assumptions applied to address 
censoring, and, as a sensitivity analysis, removing those participants experiencing major events 
(82). Long-term MELD and UKELD, measured to day 360, were assessed as per co-primaries 
1 and 2 (82). Average change in liver parameters from baseline was compared using a test 
appropriate to the data (82). Other outcome measures were reported descriptively (82). Stata 
v14 was used for all analyses (82). 
6.2 (ii): Trial population 
 
Patients were recruited from liver clinics (82). All participants gave written informed consent 
and the study was conducted by site investigators, and data were gathered by specifically 
trained personnel (82). Of 153 patients with liver cirrhosis who were screened, 81 underwent 
randomisation between 18 May 2010 and 26 Feb 2015 (82). Participants were recruited from 
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UK sites as follows: Birmingham (n=58), Edinburgh (n=19) and Nottingham (n=4) (82). 
Among 81 patients, 27, 26 and 28 patients were randomised into group 1 (standard care), group 
2 (GCSF only) and group 3 (GCSF and CD133+ cells) respectively. At day 90, primary 
outcomes were not available in 4 patients from G1, none from G2 and 2 from G3 due to death, 
deviation, and withdrawal from treatment (Figure 20) (82). 
One patient never received GCSF (withdrew from study), one patient received GCSF but no 
CD133+ cells (unable to obtain venous access for leukapheresis) and six patients received 
GCSF but did not receive sufficient cells to complete 3 full doses and therefore followed the 
protocol (82). Based on treatment received the modified intention to treat (mITT) population 
comprised 27, 26 and 26 patients belonging to Groups 1, 2 and 3 respectively (82).  
6.2 (iii) General characteristics of included patients 
 
Participant characteristics recorded at baseline (Table 9) indicated an imbalance in gender as 
women were underrepresented in group 3, whereas no differences were observed in age, 
MELD, UKELD, blood analyses, non-invasive measures of liver fibrosis and quality of life 
(82). Median MELD scores were 13.1 (12.4, 13.8), 12.7 (12.0, 13.1) and 13.2 (12.1, 13.9) 
across groups 1, 2 and 3 respectively (82). Patients had features of liver decompensation 
(ascites, encephalopathy and prior variceal bleeding) although these were mild and responsive 




Table 9: Baseline characteristics of the patients’ groups included in the clinical trial (82) 
 Standard care (n=27) GCSF only (n=26) GCSF+ CD133 cell 
infusion (n= 28) 
Demographics 
Age (years) 52.0 (47.0, 60.0) 54.0 (49.0, 61.0) 56.5 (47.5, 62.5) 
Sex: Male (n, (%)) 13 (48.1) 18 (69.2) 22 (78.6) 
Liver disease aetiology (n, (%)) 
Alcohol related liver 
disease 
12 (44.4) 12 (46.2)  14 (50.0) 
Hepatitis C 4 (14.8) 3 (11.5) 3 (10.7) 
Non-alcoholic fatty 
liver disease (NAFLD) 
5 (18.5) 3 (11.5) 5 (17.9) 
Primary biliary 
cholangitis (PBC) 
5 (18.5) 7 (26.9) 3 (10.7) 
Cryptogenic cirrhosis 0 (0) 1 (3.8) 2 (7.1) 
Mixed 1 (3.7) 0 (0) 1 (3.6) 
Liver disease severity 
MELD 13.1 (12.4, 13.8) 12.7 (12.0, 13.1) 13.2 (12.1, 13.9) 
UKELD 51.5 (49.8, 54.2) 51.1 (50.0, 52.5) 52.0 (50.9, 53.5) 
Child Pugh score 7.0 (7.0, 8.0) 7.0 (6.0, 8.0) 7.0 (6.0, 8.0) 
Child Pugh Class    
A 6 (22.2%) 7 (26.9%) 11 (39.3%) 
B 21 (74.1%) 19 (73.1%) 16 (57.1%) 
C 1 (3.7%0 0 (0.0%) 0 (0.0%) 
Unknown 0 (0.0%) 0 (0.0%) 1 (3.6%) 
Liver co-morbidities (n (%)) 
Ascites 12 (48.1) 10 (38.5) 14 (50.0) 
Variceal bleeding 7 (25.9) 11 (42.3) 11 (39.3) 
Encephalopathy 3 (11.1) 3 (11.5) 7 (25.0) 
Full blood count 
Haemoglobin (g/dL)  12.9 (11.8, 13.8)  13.1 (11.6, 14.3)  12.9 (12.1, 14.3)  
WBC (*10^9/L)  4.2 (3.3, 5.4)  4.3 (3.4, 5.2)  4.3 (3.3, 5.3)  
Platelets (*10^9/L)  77.0 (57.0, 92.0)  90.5 (54.0, 116.0)  78.5 (57.0, 106.5)  
Biochemistry 
Sodium (mmol/L)  140.0 (137.0, 142.0)  140.0 (137.0, 142.0)  139.0 (137.0, 140.0)  
Potassium (mmol/L)  3.9 (3.7, 4.4)  4.0 (3.7, 4.2)  4.1 (4.0, 4.2)  
Urea (mmol/L)  3.7 (2.7, 4.2)  3.8 (2.9, 4.8)  4.8 (3.7, 5.3)  
Creatinine (mmol/L)  62.0 (52.0, 74.0)  63.0 (56.0, 75.0)  71.0 (64.0, 90.0)  
Liver function tests (LFTs) 
Bilirubin (mmol/L)  38.0 (30.0, 53.0)  44.0 (34.0, 53.0)  41.5 (33.0, 51.0)  
Albumin (g/L)  33.0 (30.0, 37.0)  36.0 (30.0, 39.0)  35.5 (33.5, 39.0)  
AST (U/L)  44.0 (35.0, 62.0)  50.5 (37.0, 82.0)  48.0 (37.0, 62.0)  
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 Standard care (n=27) GCSF only (n=26) GCSF+ CD133 cell 
infusion (n= 28) 
ALT (U/L)  28.0 (20.0, 39.0)  31.5 (21.0, 54.0)  31.0 (21.5, 45.0)  
ALP (U/L)  160.0 (108.0, 255.0)  142.5 (118.0, 282.0)  138.5 (97.5, 244.0)  
GGT (g/dL)  68.0 (49.0, 110.0)  86.0 (57.0, 198.0)  73.0 (41.0, 188.5)  
AFP (IU/L)  3.0 (2.0, 6.0)  3.0 (2.0, 5.0)  3.0 (2.0, 5.0)  
INR  1.4 (1.2, 1.4)  1.2 (1.2, 1.4)  1.3 (1.2, 1.4) 
Non-invasive hepatic biomarkers 
Fibroscan (kPa)  32.5 (22.2, 44.8)  34.3 (26.1, 66.4)  28.9 (17.3, 45.2)  
ELF score 12.0 (11.2, 13.0)  11.9 (11.4, 12.6)  12.1 (11.3, 13.0)  
ELF: Hyaluronic acid  490.6 (265.2, 879.9)  476.9 (253.8, 722.2)  574.4 (366.8, 807.5)  
ELF: Amino-terminal 
propeptide of type III 
procollagen  
17.1 (12.0, 22.8)  18.2 (13.0, 25.7)  18.7 (13.2, 26.4)  
ELF: Tissue inhibitor 
of metalloproteinases 1  
329.3 (267.0, 399.1)  372.2 (289.5, 507.6)  322.9 (227.1, 412.2)  
Quality of life - Chronic Liver Disease Questionnaire (CLDQ) 
Abdominal  6.3 (4.7, 7.0)  5.7 (4.0, 6.7)  6.0 (4.7, 7.0)  
Fatigue  4.5 (2.8, 6.0)  3.5 (2.6, 5.2)  4.2 (3.6, 5.2)  
Systemic  5.4 (4.0, 6.2)  5.4 (4.0, 6.0)  5.2 (4.4, 6.0)  
Activity  6.0 (3.7, 7.0)  4.7 (3.2, 6.0)  5.8 (4.7, 6.8)  
Emotion  5.6 (4.5, 6.8)  4.8 (3.7, 5.8)  5.4 (4.5, 6.1)  
Worry  5.8 (3.9, 6.9)  5.1 (3.3, 6.6)  4.8 (3.6, 6.4)  
Overall  5.5 (3.4, 6.3)  4.8 (3.5, 5.5)  5.0 (4.2, 6.1) 
MELD: Model for End Stage Liver Disease, UKELD: United Kingdom Model for End Stage 
Liver Disease, AST: Aspartate transaminase, ALT: Alanine transaminase, ALP: Alkaline 
phosphatase, GGT: Gamma-Glutamyl Transferase, AFP: Alpha-feto protein, INR: 




Figure 20: Flowchart of trial randomisation (82); Modified intention to treat (mITT) population 
was defined as participants who were protocol violator, ineligible participants, and participants 
receiving at least one-day GCSF at 15mcg/kg body weight in group 2, plus one infusion of 
0.17x106 cells/kg for group 3, MELD: Model for End Stage Liver Disease, UKELD: United 
Kingdom Model for End Stage Liver Disease, AE: Adverse events 
6.2 (iv): Safety and Adverse events 
 
Safety and adverse events were assessed using standard reporting forms by trained 
investigators (82). The National Cancer Institute’s common terminology criteria for AEs 
(CTCAE V.4.02 – 2010) was used to grade each AE (82). The reporting period for adverse 
event (AEs) started from the date of patient consent and continued throughout the study until 
visit 7 (Day 360) (82). Serious adverse events (SAE’s) were reported from date of consent until 
30 days after the last possible cell infusion (Day 90) for all treatment arms, therefore ensuring 
that the reporting period stayed the same for all treatment arms (82).  
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6.2 (v): Primary outcome  
Of the mITT population a day 90 MELD score was recorded for 23, 26 and 26 patients in 
groups 1, 2 and 3 respectively (82). The median (IQR) change in MELD from day 0 to 90 for 
groups 1, 2 and 3 were -0.5 (-1.5, 1.1), -0.5 (-1.7, 0.5) and -0.5 (-1.3, 1.0) respectively (82). 
There was no difference MELD change between days 0 and 90 in groups 2 and 3 when 
compared to the control (p=0.718 and p=0.904 respectively) (82). There was no evidence of 
treatment activity in the per protocol population (82). Co-primary 2 was based on all 
participants belonging to the mITT population (82). Changes in MELD was shown in Figure 
21A, Table 10.  
6.2 (vi): Secondary outcomes 
 
In none of the analyses of UKELD was evidence of a difference between groups detected and 
no differences were detected in either composite or individual markers of liver dysfunction 
across any of the groups (Figure 21 B, Table 10) (82). Moreover, there were no differences in 
markers of liver fibrosis (serum ELF or Fibroscan) nor in quality of life scores (CLDQ) (82).  
 
Figure 21: Median change in MELD (A) and UKELD scores (B) at day 30. 60 and 90 for the 
study population (82); MELD: Model for End Stage Liver Disease, UKELD: United Kingdom 
Model for End Stage Liver Disease 
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Table 10: Change in liver parameters from baseline to day 30 and day 90 (82) 
 Group 1 (n=27)  
Standard care 
Group 2 (n=26) 
GCSF only 
Group 3 (n=28) 
GCSF and CD133 
positive cells infusion 
 Day 30 Day 90 Day 30 Day 90 Day 30 Day 90 
Liver disease severity 




































Full blood count 









(-1.6, -0.4) † 
-0.4  
(-1.0, 0.4) 































































































































































































Non-invasive hepatic biomarkers 
Enhanced Liver 
Fibrosis (ELF)  
 -0.1  
(-0.4, 0.6) 
 0.0  
(-0.4, 1.0) 




 Group 1 (n=27)  
Standard care 
Group 2 (n=26) 
GCSF only 
Group 3 (n=28) 
GCSF and CD133 
positive cells infusion 
 Day 30 Day 90 Day 30 Day 90 Day 30 Day 90 
Fibroscan (kPa)  0.0  
(-1.6, 8.6) 
 0.0  
(-11.9, 9.5) 
 0.5  
(-3.8, 10.1) 
 
Quality of life 
CLDQ, overall  0.2  
(-0.1, 0.6) 
 -0.1  
(-0.4, 0.3) 
 0.0  
(-0.2, 0.2) 
       
Values are recorded as a change in medians (interquartile range/IQR). Statistical comparisons 
were made between change at day 30 and 90 to baseline between the treatment groups, and 
unless indicated, there were no significant differences. *p=0·0017. †p=0·0006. ‡p=0·0024. 
§p=0·0002. ¶p=0·0053. MELD: Model for End Stage Liver Disease, UKELD: United 
Kingdom Model for End Stage Liver Disease, CLDQ: Chronic Liver Disease Questionnaire, 
GCSF: Granulocyte colony stimulating factor 
 
6.2 (vii): Clinical outcomes and safety 
 
None of the patients from treatment arm had a reduction in mortality nor admissions to hospital 
(82). One patient from group 1 died due to variceal bleed. No one died in GCSF group but 2 
died in GCSF+ CD133 cell group because of myocardial infarction and progressive liver 
disease (82). One patient in standard care was assessed for LT but not listed due to cardiac 
arrhythmias. Four patients from GCSF group was assessed for LT and 3 were transplanted. In 
group 3, all 3 who were assessed for liver transplantation received the organ (82). There were 
more serious adverse events recorded in group 3 compared to group 2 and group 1 (Table 11) 
(82). None of the SAE were thought to be related to treatment (82). Patients were monitored 
for a year including assessment for LT, serious AEs, standard screening for hepatocellular 





Table 11: Adverse events and clinical outcomes of the studied population in the trial (82) 
Standard care GCSF only GCSF and CD133+ cell 
infusion 
Deaths 
Variceal Bleed   Myocardial infarction   
  Progressive liver disease 
Assessed for liver transplantation 
Assessed but not listed due to 
ventricular arrhythmia  
Assessed & listed due to 
decompensation  
Transplanted  
Assessed & listed due to 
decompensation  
Transplanted  
 Assessed & listed due to 
decompensation  
Transplanted  
Assessed & listed due to 
decompensation  
Transplanted  
 Assessed & listed due to poor 
synthetic function  
Listed but removed due to 
improvement 
Assessed & listed due to 
decompensation  
Not transplanted  
 Assessed & listed due to 
decompensation, Transplanted  
 
Serious adverse events 
Admission with 
hypoglycaemia– resolved 
with no sequelae 
Admitted with oesophageal 
variceal bleed - resolved with 
no sequelae 
Admitted with diarrhoea and 
pulmonary sepsis  
Admitted with hepatic 
decompensation - died  
Admitted with urinary 
retention and ascites - 
resolved with no sequelae 
Admitted with sepsis and 
encephalopathy- resolved 
with no sequelae 
  Admitted with hepatic 
decompensation and ascites - 
resolved with no sequelae 
Admitted with acute kidney 
injury- resolved with no 
sequelae 
  Admitted with cardiac failure 
- resolved with no sequelae 
    Admitted with ascites and 
encephalopathy- resolved 
with no sequelae 
    Admitted with ascites and 
encephalopathy - resolved 
with no sequelae 
  
  
  Admitted with abdominal 








  Admitted with peripheral 
oedema- resolved with no 
sequelae 
  Admitted with sepsis and 
ascites - resolved with no 
sequelae 
  Admitted with 
encephalopathy - resolved 




This study did not show improvement in MELD in either GCSF or GCSF with stem cell 
infusion group at day 30 or day 90. For our study, MELD was chosen as a primary outcome 
since it was a validated objective scoring system used in clinical practice and it independently 
predicts risk of decompensation in patients with compensated cirrhosis (82). It is highly 
accurate in predicting mortality at 1 week, 3 months and 1 year (82). The change in MELD 
also predict the development of liver complications such as ascites and variceal bleeding (82).  
None of the secondary outcomes were shown significant across 3 groups. These findings 
contrast with studies that had been published before. Khan and colleagues studied the effect of 
CD34+ cells in 4 patients with liver insufficiency and they showed that all patients had 
improvement in biochemical markers (ALT, albumin, bilirubin and ALT) one month after the 
cell infusion (70). However, our study did not show any improvement in biochemical markers 
across all 3 groups. Andreone and colleagues (85) performed phase 1 trial to evaluate the 
feasibility and safety of CD133+ stem cells in patients with end stage liver disease and the 
study showed that among the patients had significant improvement in MELD at 2 months.  
 
Prajapati and colleagues (86) studied the efficacy of GCSF in patients with decompensated 
cirrhosis and they used 300ug BD for 5 days and the dose was lower than what we used in our 
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study (e.g.: 15 ug/kg/day – 60kg will received 900ug). Their study showed that GCSF therapy 
improved overall survival and clinical outcomes at 6 months but in our cohort, who received 
GCSF therapy, there were no difference in clinical outcomes when compared to control group. 
 
Strengths of the study 
Despite not positive impact on the outcomes, the study had several strengths since it had been 
the largest and most rigorous randomised controlled trial on haematopoietic stem cell therapy 
for patients with liver cirrhosis (82). This study also had been powered prior to trial initiation 
to detect a clinically meaningful difference. Another strength in this study was inclusion of 
GCSF group and in direct comparison with group that had stem cell infusion. There were no 
serious complications related to either GCSF or GCSF- cell infusion was recorded during the 
study follow up. We recruited patients with compensated liver cirrhosis hoping that they had a 
greater potential to regenerate which then help with regression of liver fibrosis. In this study, 
we chose purified, autologous haematopoietic stem cells (CD133+) because it represented a 
more enriched subpopulation which can potentially have a greater impact on regression of liver 
fibrosis. In this study, stem cells were given via a peripheral vein and this mode of cells delivery 
had better safety profile compared to more advanced methods of delivery such as portal vein 
or hepatic artery.   
 
Limitations of the study 
There are few limitations with our study and one of them is not to have histological endpoint 
as part of the outcome. Performing liver biopsies pre- and post-therapy in the space of 12 
months can put significant risk to the patients since most of the liver patients had coagulopathy. 
Even with liver biopsies, the interpretation can be misleading in cirrhotic patients due to 
presence of regenerative nodules and may not reflect true degree of disease severity. Liver 
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biopsies were also not without significant risk such as bleeding, infection, perforation and even 
death. Although MELD score is user friendly and widely accepted in hepatology community 
in risk stratifying patients with liver cirrhosis, it may not have been a good marker to detect a 
change in degree of liver fibrosis. The reason being is that to actually see a significant change 
in liver fibrosis, we will need significant reduction in MELD score. As per Figure 6, patient 
with MELD of 30 have about 60% survival compared to 85% survival in patient with MELD 
of 20 which means the patients need to have a 10-point reduction. Change in MELD of 1 or 2 
points did not reflect the improvement of liver fibrosis. 
 
In clinical settings, we use hepatic venous pressure gradient (HVPG) measurement to detect 
liver stiffness. In a study by Ripoll (87) showed that each 1mmHg rise in HVPG was associated 
with 3% mortality risk in patients. HVPG may be a better representative of liver fibrosis 
although most of the stem cell studies that had been conducted never included HVPG as an 
outcome of interest. Although there is a risk with the procedure of getting HVPG, the risk is 
much less than having a liver biopsy. For future studies of stem cells therapy, we need a better 
biomarkers or more precise imagining to detect a meaningful outcome.  
 
The other limitation was that we did not track the cells in vivo to understand the homing of 
cells to the liver. The reasons for not doing so was due to technical and regulatory barriers as 
well as uncertainty in the viability and efficacy of the stems post labelling. Another limitation 
was the delivery of the cell therapy. We used peripheral route instead of the central route due 
to its ease in delivering the cells especially when we planned to give the cells in 3 separate 
infusions. Although the central route potentially can be more effective than peripheral route, it 
is invasive with serious risk as in thrombosis and bleeding (82).  
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In our study, we recruited patients with various causes of liver cirrhosis and felt that these 
groups of patients might have reflected the overall population of liver diseases in daily clinical 
practice. The assumption was that the final mechanism towards liver fibrosis may be the same 
irrespective of the causes of liver diseases. However, each cause of liver cirrhosis may have 
different pathway into pathogenesis of liver fibrosis. The other reason that haematopoietic stem 
cells were not effective in our cohort was likely to be related to the underlying diseased liver 
fibrosis.  There was a possibility that the disease liver itself did not have the ability to repopulate 
the cell populations which were also failed despite giving external stimuli such as GCSF 
injection.  
 
In summary, our study showed that GCSF alone or GCSF with stem cell infusions did not 
showed any clinical benefit in patients with liver cirrhosis. This result varies from currently 
published studies although most studies had less patients with less inferior study design (either 
phase I or II). Even with GCSF, we used the dose higher than most studies in literature, but we 
did not see any improvement in clinical outcomes. In mice model of liver injury, we showed 
that repeated HSC infusions improved liver fibrosis but in human study, the study did not show 
an improvement in liver fibrosis which was most likely due to underlying complexity in 
pathogenesis of liver fibrosis/cirrhosis in human.  
 
If I have another opportunity to conduct this clinical trial again, I will consider recruiting 
dedicated cohort of patients with liver cirrhosis such as alcohol related liver cirrhosis or non-
alcoholic fatty liver disease. There is a possibility that crosslinking pattern of collage in the 
liver may be different between patients with different causes of liver diseases as well as 
different stages of liver cirrhosis. By choosing particular group of liver disease will give us an 
opportunity to understand the underlying mechanism of liver fibrosis and how the stem cells 
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can have an effect on liver fibrosis. We should also attempt the basic science research alongside 
the clinical trial to understand the mechanistic action of stem cell in liver regeneration. I will 
also choose patients with lower and tighter range of MELD score for example MELD between 
10 and 12 instead of our MELD score of 11.5 to 15.5. I felt that our range of MELD in this 
clinical trial was broad and as a result, we had a heterogenous populations with different stages 
of liver cirrhosis and stem cells have not have effect on patients with more advance fibrosis. 
By narrowing the range of MELD, patients recruited may have similar degree of fibrosis stage. 
We also other means to better define the underlying degree of liver damage such as having a 
liver biopsy prior to enrolling into the clinical trial or having a measurement of HVPG or even 
using a more robust biomarkers or imaging technique. Although 12 months is a good duration 
of follow up, we will need longer duration of follow up to actually see the benefit of stem cells 
on liver fibrosis although it may not be feasible due to timing with recruiting patients as well 
as costs of running the trials.  
 
This is the first ever randomised controlled clinical trial and we did not see benefit in 
improvement of liver fibrosis. If we ever need to perform another clinical trial, we need to 
better define a population of liver cirrhosis and stem cells of interest.  The trial should look into 
ways of tracking the stem cells which will give us better understanding of the viability and 
efficiency of the stem cells. Most studies have these clinical outcomes such as patient’s 
survival, MELD score and liver elasticity although those outcomes did not detect any 
therapeutic effect of cell therapies. We should look into other outcomes such as changes of 
HVPG or even spleen elastography which are more representative of liver fibrosis.  
 
Due to inconsistent findings of clinical outcomes with stem cell therapies, a systematic review 
and meta-analysis had been conducted to critique the current published literatures. In 2017, 
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there had been nine systematic reviews looking at stem cells in liver diseases mostly in 
“mesenchymal stem cells”. The studies searched for those systematic reviews were performed 
only up to 2015 and hence, a new study is needed including the clinical trial that I was involved 
in. Our trial was a randomised controlled trial which involved largest number patients and 
hence, by conduction a systematic review including our data, it will give us better 
understandings on the efficacy of haematopoietic stem cells therapy in patients with liver 
cirrhosis. The detailed methodology and the results of the systematic review had been 
documented in Chapter 7 and 8 of this thesis.  
 
Overall, we did not an improvement of liver fibrosis in our cohort of patients, we do not feel 
that patients with decompensated cirrhosis will achieve benefit from stem cells therapy. Stem 
cells therapy has a degree of short term benefit on the resolution liver fibrosis although we may 
need to perform studies with more robust, well designed clinical trials with alternative 
interested outcomes. It is also really important to track the cells in human trials to understand 
the nature of stem cells and hopefully will give us a better way to deliver the stem cells to 





7. SYSTEMATIC REVIEW AND META-ANALYSIS 
 
7.1 Introduction  
 
The systematic review protocol paper had been published recently (I was the author) and the 
session below were from the published manuscript (88).  
The systematic review project has been registered with PROSPERO (International prospective 
register of systematic reviews) and the trial registration number is CRD42016016104.  
7.1 (i): Role within the clinical trial 
 
My responsibilities include 
1) Writing the systematic review protocol 
2) Registration of systematic review on the PROSPERO website 
3) Performing thorough searches using MESH and free search terms on the databases 
mentioned in the protocol 
4) Screening of titles and abstracts using the pre-identified study form 
5) Screening of full articles 
6) Performed data extraction, quality assessment of the included studies 
7) Performed data analysis using “Revman” software 
8) Final writing up of the results 
7.2: Methodology 
 




Up to September 2017, there had been nine systematic reviews and meta-analysis of stem cell 
therapies in patients with both chronic liver disease and ACLF (Table 12) (44, 64, 89-95).  
Across all the reviews, each study had their own strengths and limitations. Most studies 
mentioned both targeted population (either CLD or ACLF) and cell therapies (MSC or GCSF) 
that were of interest but one study in particular (95) was unclear on the target population but 
only mentioned of as liver failure patients which can be either acute, acute-on-chronic or 
chronic liver failure. Most studies combined different study designs when analysing data that 
can obscure the interested outcomes. Two studies (90, 93) used all types of stem cells and the 
outcomes can vary due to heterogeneity seen with different stem cells.  Other issues noted from 
these current published studies were less elaborative search strategies, analysis of difference 
cell therapies together and lack of clarity on limitations of (or reason for not) conducting meta-
analysis or subgroup analysis (88). The current published studies had been critically appraised 
using PRISMA 2009 checklist prior to starting this current review (appendix 5).  
In current published systematic reviews, the searches of the studies were up to 2015. Since 
2015, there had been few more original studies (57, 82, 86, 96, 97) and we felt that a new 
systematic review is needed. In this review, the searches were updated to September 2017. In 
addition, we hoped to address the limitations that was noted before. We aim to cluster studies 
according to the study designs, the populations and the stem cells of interest when performing 
meta-analysis.   
Table 12: Current published systematic reviews and meta-analysis of stem cell therapies in 
















China Any types of 
studies  
CLD Any types of stem 




1) Short term and long-term efficacy  
2) Assessment of liver function indices 




























ACLF GCSF alone or in 
combination 
Primary outcomes 
1) Overall mortality 
2) Mortality due to organ failure 
3) Adverse events 
 
Secondary outcomes 
1) Complications  
2) Hospitalisation length 
3) Liver transplantation 4) Changes in 
severity indices (CTP, MELD, SOFA) 
5) Mortality secondary to gastrointestinal 
bleeding 
6) Changes in peripheral leucocytes and/or 
neutrophils counts 










Korea 1) Before-after 
study 







3) Case series 
2) Changes in liver function tests and 
associated prognostic markers of liver 











letter to editors, 
case series with 
only experimental 
arm 
CLD Autologous bone 
marrow MSC 








China Any type of 
studies 
CLD Any types of stem 
cells 
1) Changes in liver function before and after 
therapy 
2) Difference in liver function between stem 
cell therapy and conventional treatment 
3) Difference in incidence of procedure 
related complications between stem cell 
therapy and conventional treatment 
4) Difference in incidence of hepatocellular 
carcinoma between stem cell therapy and 
conventional treatment 
5) Difference in incidence of death between 
















CLD Autologous bone 
marrow stem cell  
1) Analysis on common symptoms and sings 
2) Analysis on levels of ALT, ALB, TBIL, 
PT/PTA/INR, MELD score, Child-Pugh 
score 












Any type of 
studies 
CLD Autologous stem 
cell therapy (any) 
Primary outcomes 
1) Safety and feasibility of the therapy 
 
Secondary outcomes 
1) Prognostic liver scores 
2) Survival 






China Any type of 
studies 






7.2 (ii): Aims and Objectives 
 
The aim of this systematic review was to evaluate the clinical effectiveness of cell therapies in 
patients with CLD or ACLF (88).  
Standard systematic review methodology aimed at minimising bias will be employed (88). 
Where data allowed, the intention was to consider, through sub-group analysis; the evidence 
of effect in different underlying disease populations (as in viral hepatitis or alcohol related liver 
diseases), the effect of each type of stem cells (HSC, MSC, unsorted stem cell or GCSF therapy 
alone), the source of the stem cells (autologous and allogeneic stem cells) and the route of 
administration of the cells such as peripheral or central route (88).  
Determination of comparative effectiveness between cell types and routes of administration 
would be considered if there were direct comparisons in studies included in the reviews. In 
addition, the potential for indirect adjusted comparisons would be assessed (88). 
7.2 (iii): Type of studies 
 
All studies were included irrespective of their study designs (88). Controlled trials (either 
randomised or non-randomised) were included (88). All observational evidence was obtained, 
whether controlled or uncontrolled, in order to gain an overview of existing observational 
evidence (88). Uncontrolled observational studies were used where primary outcomes are not 
reported in the controlled studies, or, where uncontrolled studies had longer follow-up for these 
outcomes (88). Existing systematic reviews will be selected to identify any primary studies that 
were not identified by the searches (88).  
7.2 (iv): Types of participants 
 
Inclusion criteria: Adult patients (≥18 years old) with   1) CLD and 2) ACLF  
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Exclusion criteria: 1) Patient with acute liver failure (no evidence of liver cirrhosis) 2) Patient 
with cancer (unable to ascertain the effect of stem cells on tumour pathogenesis) (88).Studies 
on mixed populations of those defined under inclusion and exclusion criteria will only be 
included where the data for CLD or ACLF is presented separately (88). 
7.2 (v): Types of interventions  
 
1) Treatment with HSC of any dose, duration and mode of delivery with standard medical 
therapy with or without GCSF therapy to mobilise stem cells for collection/harvesting 
2) Treatment with MSC from any source, any dose, duration and mode of delivery with 
standard medical therapy. 
3) Treatment with unsorted stem cells (BMSC and/or BM-MNC) of any dose, duration 
and mode of delivery with standard medical therapy with or without GCSF.  
4) Treatment with GCSF therapy only (without stem cell infusion) of any dose and 
duration with standard medical therapy. 
7.2 (vi): Comparator 
 
Comparator include standard care, placebo, other stem cells as a comparator or using different 
route as comparator.  
7.2 (vii): Types of outcome measures 
 
There was no restriction placed on the type of clinical outcomes or the duration of follow up 
for study selection to capture the additional evidence of adverse events occurring close to the 
time of stem cell infusion or GCSF injection (88). Primary and secondary outcomes interested 




1) Overall patient survival 
2) Liver transplant free survival 
3) MELD 
4) Quality of life 
5)  Adverse events specific to the intervention 
Secondary outcomes 
1) Liver function tests  
2) Child Pugh Score 
3) Events of liver decompensation as defined and reported by the study authors.   
7.3: Search strategy 
 
Cell therapy in liver diseases was first investigated in clinical phase studies in early 2000s and 
hence, the searches will be run from year 1990 onwards. The following databases will be 
searched to capture both published and unpublished studies.  
1. Bibliographic databases - MEDLINE, MEDLINE in Process and EMBASE, Cochrane 
Library CENTRAL database for published studies and additionally for systematic reviews the 
Cochrane Library Database of Systematic Reviews, Health Technology Assessment database 
and The Database of Abstracts of Reviews of Effects 
2. The International Standard Randomised Controlled Trial Number (ISRCTN) database, 
United Kingdom Clinical Research Network (UKCRN), WHO International Clinical Trials 




3. Hand searching of conference reports from the following databases between January 
2012 and September 2017: The European Association for the study of Liver Disease, American 
association for the study of liver disease, Asian-Pacific association for liver disease, British 
association for the study of liver disease and British society of gastroenterology.  
4. Screening of citation lists of included studies and relevant systematic reviews 
Database were searched with a combination of MeSH terms and text words for the population 
and the interventions as appropriate (88). No language restrictions were applied to the searches 
(88). Study design filters was not used (88). The detail of the search strategy can be found in 
appendix 3. Search results are entered into Endnote version X7.02, Thomson Reuters to 
facilitate with record keeping, duplicate removal and study selection (88). Full-text articles 
were retrieved, and the data were entered into Microsoft Excel spreadsheet for data extraction 
and risk of bias assessment (88).  
7.4: Data collection and analysis 
 
7.4 (i): Selection of studies 
 
To remove irrelevant articles, I screened all the titles and abstracts and to ensure consistency, 
another reviewer checked a proportion (minimum 50% of all articles) independently (88). This 
way of screening articles was a limitation of the study due to this project being unfunded. Hard 
copies of relevant articles were acquired and assessed independently against the inclusion 
criteria by two reviewers (88). Discrepancies between reviewers were resolved by discussion 
and by referring to a third reviewer if required (88). Full text selection was performed by myself 
and another reviewer independently (88). Where necessary, translation (full/part) of non-
English language articles was planned to undertake to facilitate this process and subsequent 
reviewing (88). Due to time constraint, translations were not possible, and this limitation was 
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reported in discussion (88). Study selection process is illustrated using PRISMA flow diagram 
(Figure22). 
 
Figure 22: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
flow chart of the systematic review 
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7.4 (ii): Data extraction and management 
 
I extracted the data from the included studies was performed using a standardised data 
extraction form (appendix 6) and checked independently by a second reviewer for all the 
studies (88). Disagreements will be resolved through discussion or referral to a third reviewer 
(88). For each study, the data required on (but not limited to) the following will be sought:  
1. Study characteristics: authors, geographical origin, year of publication, study design (to 
include bias/confounding minimisation), years and duration of recruitment, number of arms, 
sample size, duration of follow up. 
2. Participant characteristics: enrolment criteria, age, sex, number of participants, diagnosis and 
disease manifestations. 
3. Intervention and comparator details: sample size for each treatment arm, dose and type of 
interventions/comparator (HSC, MSC, unsorted stem cell or GCSF therapy alone), type of 
treatment received before or during therapy and the duration of treatment. 
4. Results: outcomes measured, time points, method of assessment, completeness of follow-
up, statistical methods employed, findings, effect sizes and associated uncertainty. 
There was likely to be a limited number of RCT on this topic and therefore as mentioned 
previously all observational evidence was obtained, whether controlled or uncontrolled, to gain 
an overview of existing observational evidence (88). However, the uncontrolled observational 
studies were only analysed where primary outcomes did not report in the controlled studies, or, 
where uncontrolled studies had longer follow-up for these outcomes (88). To facilitate this 
decision making and to be efficient, data from controlled studies was extracted first and data 
from uncontrolled studies would be extracted when needed (88).  




Data was extracted to allow quality assessment of the included studies (88). Study quality was 
assessed using tools specific to a given study design. The risk of bias tool from the Cochrane 
Handbook was used for RCTs [91]. For non-RCT studies, the domains in the risk of bias tool 
for RCTs was used as a minimum assessment (accepting that the studies are not randomised) 
(88). Regarding RCT and non-RCT, the risk of bias assessment was documented as “high risk”, 
“low risk” or “unclear risk”.  
For controlled observational studies, the guidelines outlined in Chapter 13 of the Cochrane 
Handbook was used (88) and in this manuscript, the selected studies were assessed using 
Newcastle- Ottawa Scale (98).   
7.6: Analysis 
 
Initially, the plan was to perform a narrative synthesis of evidence. The analysis was planned 
based on the type of cells (HSC, MSC, BMSC or GCSF), by population (CLD or ACLF) and 
by outcomes interested. Subgroup analysis was considered to investigate based on the source 
of stem cells (allogeneic and autologous) or the route of administration (central or peripheral 
infusion) if feasible to extract the data. Analysis methods was guided by the considerations 
outlined in the Cochrane Handbook (99). Meta-analytic methods will be employed where 
appropriate, to combine data for each population, comparison, outcome combination across the 
same, or very similar time points.  
Data integration and analysis were performed using review manager (RevMan Cochrane 
Collaboration) version 5.3 software. Subgroup analysis will be considered where appropriate 
based on the type of stem cells, the source of cells and the route of administration. Meta-
analysis was performed where appropriate, to combine data for each population, comparison, 
outcomes across the same or similar time points. Results for dichotomous data were expressed 
as odds ratio (OR) with 95% confidence interval (CI). OR of each study were combined to give 
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a pooled OR. Mean and standard deviations were extracted from continuous data and measured 
as mean difference (MD) with 95% CI. Standard mean difference (SMD) of each study was 
combined to give a pooled SMD. The significance of pooled estimates was assessed with Z 
tests in in which p-value of <0.05 was considered statistically significant. The heterogeneity 
between studies were assessed with Chis square based Q test and I2 statistic. Chi-square tests 
(p<0.1) and I2>50% was considered to represent significant statistical heterogeneity. If P≥0.1 
and I2 ≤50%, fixed effects models was used but otherwise, random effects model was used.  
7.7: Reporting of data 
 
The review and its findings will be reported in accordance with the Preferred Reporting Items 




8: RESULTS OF SYSTEMATIC REVIEW AND META-ANALYSIS 
 
8.1: Search outcomes 
 
Using the search criteria listed in appendix 3, searches were done up to week 3 of September 
2017.  A total of 22,011 records were identified through database searching with 1,581 records 
from Medline, 201 records from Medline in Process and 20,229 records from Embase. An 
additional 37 records were identified through other sources such as conferences, hand searching 
and references. After removing duplicates (n=1,825), 20,223 records remained. After screening 
titles and abstracts of those records, a further 20,032 were excluded. Finally, 191 full text 
articles were assessed for eligibility using the pre-set checklist (appendix 6). Among them, a 
further 31 were excluded and the reasons for exclusion were shown in Figure 22 and Appendix 
4. Finally, 160 articles with 103 studies were included in qualitative studies and 35 studies were 
eligible for quantitative analysis (Figure 22).  
8.2: Quality assessment of the included studies 
 
The quality assessment of RCT and non-RCT studies were performed using Cochrane risk of 
bias assessment tool. For controlled studies, Newcastle-Ottawa scale was used for 
methodological assessment. The risk of bias for RCT and non-RCT studies for CLD and ACLF 
were presented as RevMan’s risk of bias graph (Figure 23 A-C). For controlled studies, the risk 




Figure 23: Risk of bias assessment graphs using Cochrane risk of bias assessments tool: A: 
Randomised controlled trial for Chronic liver failure, B: Non-randomised controlled trial for 
Chronic liver failure, C: Randomised controlled trial for Acute on chronic liver failure. 
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Table 13: Risk of assessments for controlled studies (both chronic liver failure and acute-on-chronic liver failure) using Newcastle-Ottwa Scale: 
A summary table (* equals 1 score) 
Chronic liver failure 
  Selection       Comparability Outcome     
  Representativeness 
















of cohorts on 















Paper * * * * ** * * * 
Peng L 
2011 (102) 
Conference * * not 
mentioned 
* * * * * 
Shi M 2010 
(103) 
Conference * * not 
mentioned 
* * * * * 
Shi M 2017 
(104) 
Conference * * * * * * * * 
Shi M 
2016(105) 
Conference * * * * * * * * 
Salama H 
2012(106) 
Paper * * * * ** * * * 
Zhu J 
2013(107) 
Conference * * * * * * * * 
Iwamoto 
2012(108) 
Paper * * * * * * * * 
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Conference * * * * * * * * 
Gaia S 
2013(111) 
Paper * * * * ** * * * 
Gaia S 
2011(112) 
Conference * * not 
mentioned 
* * * * * 
Gaia 2006  
(113) 
Paper * * * * * * * * 
Lin S 
2017(114) 
Conference * * * * * * * * 
Acute on chronic liver failure 
Shi M 
2012(115) 
Paper * * * * ** * * * 
Weng WZ 
2013(116) 
Conference * * * * * * * * 
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8.3: Results of outcomes 
 




There were 22 randomised controlled studies (56, 82, 86, 96, 97, 117-133), 17 non-randomised 
controlled studies (61, 134-149), 14 controlled studies (101, 104, 106-111, 113, 114, 150-153) 
and 50 studies with no controls (53, 60, 85, 154-200). The studies were conducted in these 
countries: Austria (n=2), Brazil (n=1), China (n=47), Egypt (n=10), Greece (n=1), India (n=8), 
Iran (n=4), Italy (n=6), Japan (n=10), Korea (n=1), Malaysia (n=1), Republic of Belarus (n=1), 
South Korea (n=2), Spain (n=1), Sweden (n=1), Switzerland (n=2), Turkey (n=1) and United 
Kingdom (n=4). Among those studies, 84 were full paper publications and 19 were conference 
abstracts. The types of stem cells were as followed: BMSC (n=28), BMSC with GCSF (n=4), 
GCSF (n=7), both HSC and MSC infusion (n=1), HSC without GCSF (n=2), HSC with GCSF 
(n=21), MSC without GCSF (n=27), MSC with GCSF (n=1), other cell types (n=6), SCT (n=1), 
Peripheral blood stem cell (PBSC) without GCSF (n=1) and PBSC with GCSF (n=4). Cells 
were extracted from adipose tissue (n=1), bone marrow (n=51), fetal liver cells (n=2), GCSF 
with no cell collection (n=7), GCSF with peripheral blood collection (n=24), umbilical cord 
(n=12) and no data available (n=6). The cells were delivered by portal vein followed by 
peripheral infusion (n=1), hepatic artery (n=44), hepatic artery or portal vein (n=8), hepatic or 
splenic artery (n=1), intrahepatic (n=3) or intra-splenic (n=2), intra-parenchymal (n=1), 
peripheral vein (n=20), portal vein (n=6), no cells delivery involved (n=7) and no data available 
(n=12).  
The details of each included study were shown in Table 14.  
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Table 14: Summary of the included studies for chronic liver disease 
Author 
name 
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4 in 
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a T 2014 
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Turkey Conference Mixed 
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a P 2009 
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Sweden Paper Mixed 
aetiologies 
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marrow 
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million 
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China Paper Hepatitis B TIPS and 
BMSC 
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not 
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5 0 not 
mentioned/ 
clinical 



















4 0 6 
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62 0 not 
mentioned 
BM: Bone marrow, MSC: Mesenchymal stem cell, SMT: Standard medical therapy, UC: Umbilical cord, GCSF: Granulocyte colony stimulating 
factor, IV: Intravenous, MNC: Mononuclear cell, TIPS: Transjugular intrahepatic porto-systemic shunt, BMSC: Bone marrow stem cell, BMC: 
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Bone marrow cell, ABMI: Autologous bone marrow infusion, HA: Hepatic artery, PV: Portal vein, UDCA: Ursodeoxycholic acid, PBC: Primary 
biliary cholangitis, ALT: Alanine transaminase, Bil: Bilirubin,   ALT: Alanine transaminase, PT: Prothrombin time, Alb: Albumin
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8.3.1: CLD and granulocyte colony stimulating factor (GCSF) therapy 
 
Study characteristics 
There were 5 RCT studies (82, 86, 120, 128, 130), 2 controlled (111, 113) and 2 uncontrolled 
studies (173, 177) that examined the effect of GCSF therapy in CLD patients. The longest 
duration of follow up was 12 months in 2 of the RCT studies (82, 120) and 1 controlled study 
(111) and therefore, only RCT studies are included in both quantitative and qualitative analysis. 
The doses of GCSF varied between the studies as noted in Table 15.  
Table 15: GCSF (Granulocyte colony stimulating factor) dose variations noted in the included 
studies for chronic liver disease  
Study ID GCSF details 
Randomised controlled trial 
Newsome P 2017 (82) 15 ug/kg/day for 5 days 
Yu S 2017 (130) 5 ug/kg/day for 3 days 
Kedarisetty C 2015 
(120) 
5 ug/kg/day for 5 days and then every 3rd day for 12 total doses 
Prajapati R 2017 (86) 5 ug/kg twice a day for 5 days 
Spahr L 2008 (128) 10ug/kg/day for 5 days 
Controlled studies 
Gaia S 2013 (111) 5 ug/kg twice a day for 3 days, repeated every 3 months for 4 courses 
Gaia S 2006 (113) 5 ug/kg twice a day for 3 days 
Non-controlled studies 









Overall patient survival: Overall patient survival showed an improvement towards GCSF 
treated group in both 6 months and 12 months duration. The analysis showed that GCSF group 
significantly less mortality than SMT group at 6 months (OR=0.45, 95% CI: 0.26-0.78, 
P=0.005) but no effect at 12 months (Figure 24).   
 
Figure 24: Overall patient survival in patients with chronic liver disease who had GCSF 
(Granulocyte colony stimulating factor) compared to standard medical therapy (SMT) at 6 
months and 12 months of follow up 
Liver transplant free survival: Three studies (82, 86, 120) examined the effect of liver 
transplant free survival. There was no improvement in LT free survival in GCSF compared to 
the SMT group at 6 months (OR=2.23, 95% CI: 0.61-8.17, p=0.23) and at 12 months 




Figure 25: Liver transplant free survival for patients with chronic liver disease who had GCSF 
(Granulocyte colony stimulating factor) compared to standard medical therapy (SMT) at 6 
months and 12 months of follow up 
MELD: In Newsome et al (82), there was no difference in MELD score between GCSF and 
SMT groups at days 30, 60, 90 and 360. Yu et al study (130) also mentioned that there was no 
statistical difference in MELD between two groups over 6 months FU. Kedarisetty et al study 
(120) showed that at 12 months, GCSF group had significantly improved MELD reduction by 
40.4% compared to 33% in SMT group (p=0.03) (120). Spahr et al study (128) showed that at 
1 month, MELD reduction was better in SMT when compared to baseline but not in GCSF 
group.  
QoL: Only one study (82) had data for quality of life (Chronic Liver Disease Questionnaire 
score) and there was no difference in overall score between GCSF and SMT groups at day 90 
[median (IQR): GCSF: -0.1 (-0.4 to 0.3) vs SMT: 0.2 (-0.1 to 0.6)].  
Adverse events to intervention: All studies showed good safety profile with GCSF therapy. 




Table 16: Safety profile of GCSF (Granulocyte colony stimulating factor) therapies in included 
studies of chronic liver disease 
Study GCSF group (Safety profile) 
Newsome P 2017 
(82) 
No serious events noted 
Yu S 2017 (130) Well tolerated 
None had splenic rupture 
Kedarisetty C 
2015 (120) 
Malaise in 37%, generalised discomfort 23% after GCSF injection 
None had portal vein thrombosis 
Prajapati R 2017 
(86) 
Safe and none had significant adverse effects.  
Some patients had nausea, vomiting and body ache resolved with symptomatic 
treatment. 
Spahr L 2008 
(128) 
Well tolerated. No spleen tenderness.  




Liver function tests: Only one study (82) had biochemical and coagulation blood tests (AST, 
ALT, Bilirubin, Albumin, INR) data and there was no improvement in GCSF group at 1 month 
and 3 months compared to baseline which was similar to SMT group.  
Child Pugh Score: One study (128) showed significant improvement (p<0.05) of CPS 1 week 
after GCSF therapy. Two studies (120, 128) showed significant improvement (p<0.05) of CPS 
in GCSF group at 1-month FU but not in another study (82). At 3 months FU, 2 studies (86, 
120) showed significant improvement (P<0.05) of CPS in cell therapy group but not in one 
study (82). At 6 months FU, 2 studies (86, 120) showed significant improvement (p<0.05) of 
CPS in GCSF group.  
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Liver decompensation events: In two studies (82, 130), liver cancers were not detected during 
the study period in GCSF cohort but in another study (120) one patient from the GCSF group 
developed a small hepatocellular cancer (HCC) by 12 months of follow up. In addition, 3 
patients developed hepato-renal syndrome (HRS) in the GCSF group compared to 3 patients 
from the SMT group (120). The number of patients who developed spontaneous bacterial 
peritonitis (SBP) was similar between GCSF and SMT groups as per studies from Kedarisetty 
et al (120) and Spahr et al (128). Sepsis rate was significantly lower in GCSF group vs SMT 
group (6.9% vs 38.5%, p=0.005) at 12 months of FU in Kedarisetty et al study (120). Three 
studies (82, 120, 130) mentioned that no one from GCSF group had hepatic encephalopathy 
(HE) during the study follow up. In Newsome et al study (82), 1 patient developed ascites at 2 
months and 3 months respectively compared to 10 patients at baseline in GCSF group. In 
Kedarisetty et al study (120), the percentage of patients requiring large volume paracentesis in 
GCSF group was significantly reduced from baseline to 1 month, 3 months and 6 months 
compared to SMT but there was no difference at 9 and 12 months between GCSF and SMT 
groups.  
8.3.2: CLD and mesenchymal stem cell therapy (MSC) 
 
Study characteristics 
There were 8 RCT studies (56, 97, 117, 125, 129, 131-133), 4 non-RCT studies (139, 144, 146, 
147), 3 controlled studies (102, 104, 109) and 14 uncontrolled studies (154, 156, 159, 165, 166, 
170, 172, 176, 182, 191, 192, 194, 199, 201). RCT studies had the longest duration of follow-
up and they were included in quantitative analysis.  
In RCT, 4 studies examined the effect of allogenic BM-MSC (56, 97, 117, 129) and 2 studies 
examined the effect of allogenic UC-MSC (132, 133). In a study by Zekri A et al (131), the 
study group received autologous haematopoietic stem cells initially followed by mesenchymal 
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stromal cells and they are included in both the analysis of HSC and MSC when deemed 
appropriate. In Salama H et al study (125), the treatment group received autologous MSC with 
GCSF. The ways that MSC were given in these studies include: hepatic artery (97, 129), portal 
vein (131), peripheral vein (56, 125, 133), intrasplenic/intrahepatic (131) and unclear route 
(132).  
Primary outcomes 
Overall patient survival: One study showed that three patients from MSC group died of liver 
failure compared to none in SMT group (56) but in another study (131), 5 patients died in each 
group from decompensated liver disease during the 12-month FU period. For 6 month FU data, 
one study showed that 5 patients died in SMT group with decompensated liver disease but no 
one died in MSC group (125). Overall, at 12 months, there was no difference in survival 
between two groups (OR=1.24, 95% CI: 0.09-16.42, p=0.87) (Figure 26).  
 
Figure 26: Overall patient survival in chronic liver disease patients who received mesenchymal 
stem cell (MSC) therapy compared to standard medical therapy (SMT) at 12 months of follow 
up 
LT free survival: There were no data available on liver transplant free survival with MSC 
therapy.   
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MELD: In a study by Xu L et al (129), MELD improved significantly in MSC group over 24 
weeks duration compared to baseline as well as to SMT group. In another study (132), it 
mentioned that MELD was improved in both MSC and SMT groups but the difference between 
them was not significant at 3, 6 and 13 months duration. A study by Zhang et al (133), there 
was a significant improvement of MELD in MSC group from week 2 to 48 as well in in control 
group from week 8 to 48 and when compared MSC to control group, the significant difference 
was only noted at week 48 only. Salama H et al (125) noted that there was a significant 
difference in MELD score between MSC and SMT groups from week 2 till end the of the study 
at 6 months’ time. In few studies (56, 117, 131), data were able to combine to review the effect 
of MSC in 3, 6 and 12 months. MELD was significantly improved in MSC treated group at 3 
months (MD -2.39, 95% CI: -3.07, -1.71, p=<0.00001) and 6 months (MD -2.97, 95% CI: -
3.71, -2.23, p=<0.00001) but not at 12 months (MD -1.17, 95% CI: -2.91, 0.57, p=<0.19) 




Figure 27: Model for End Stage Liver Diseases (MELD) score changes in chronic liver disease 
patients who had mesenchymal stem cell therapy (MSC) compared to standard medical therapy 
(SMT) at 3 months, 6 months and 12 months of follow up 
 
QoL: There were 2 studies (117, 132) that had outcomes for quality of life. One study (117) 
showed that there was an improvement in fatigue score after 2 weeks with the maximum effect 
observed at 1 month, which was maintained for 6 months as well as a significant improvement 
in performance scale from 2 weeks up to 6 months. The other study (132) showed that there 
was a significant improvement in QoL at 1 month although the effect was not maintained at 3 
or 12 months. From these two studies, it appeared that MSC therapy seemed to have a short 
term beneficial effect on QoL.  
Adverse events from intervention: Fever is a very common adverse event noted with MSC 
therapy (97, 117, 129, 131-133) and in most cases, fever tended to subside 12 hours post 
therapy. No other serious adverse events were recorded in any of the studies. From the analysis, 
19 patients in total had fever in MSC group compared to none in SMT group (OR=9.87, 95% 
CI: 2.17, 44.92, p=0.003) (Figure 28). 
 
Figure 28: Incidence of fever seen in chronic liver disease patients who had mesenchymal stem 




Liver function tests: A study by Mohamadnejad et al (56) mentioned that serum transaminases 
level between MSC and SMT group did not differ at 12 months of duration. In Xu L et al (129), 
ALT improved significantly at week 1, 2, 4, 8, 12 and 24 weeks in both MSC and SMT group 
compared to baseline (p<0.05) although there was no data comparing MELD between MSC 
and SMT at each time-point. Amer et al study (117) did not show any difference in liver 
enzymes in both MSC and SMT group at 6 months duration. Zheng et al study (132) mentioned 
that liver function improved in both MSC and SMT groups at 1, 3 and 12 months but there was 
no difference between the groups. Salama et al paper (125) mentioned that ALT fold improved 
significantly in MSC group at 6 months compared to SMT group (p=0.029), but not at other 
time points (2 weeks, 1 and 3 months). Salama et al paper (125) showed that AST fold change 
was only significant at the 3 month time-point in MSC compared to control (p=0.48) but not at 
week 2, 1 month and 6 months.  In Suk et al paper (97), ALT and AST improved in both MSC 
and SMT group at 12 months compared to baseline but there was no difference between the 
two groups.   
Xu et al study (129) mentioned that bilirubin improved significantly in MSC group from week 
1 to week 24 when compared to baseline but was only significant at 24 weeks when compared 
to SMT group (p<0.05). Zhang et al study (133) mentioned that bilirubin was improved 
significantly in both MSC and SMT group from weeks 4 to 48 compared to baseline but only 
significant at week 48 when MSC were compared to SMT (p<0.05). In Amer et al study (117), 
there was no difference in bilirubin between MSC and SMT groups at 6 months. From Zekri 
(131), Suk (97) and Salama (125) studies, bilirubin data were combined to perform analysis at 
2 weeks, 1, 3, 6 and 12 months. From the analysis, bilirubin was significantly improved in 
MSC group at 6 months only (MD: -13.5, 95% CI: -26.16, -0.83, p<0.04) but not at 1 week, 1 




Figure 29: Bilirubin changes seen in chronic liver disease patients who had mesenchymal stem 
cell therapy (MSC) compared to standard medical therapy (SMT) at week 2, 1 month, 3 
months, 6 months and 12 months of follow up 
Xu et al study (129) showed that albumin improved in both MSC and SMT groups at 2, 4, 8, 
12 and 24 weeks compared to baseline and when compared MSC to SMT groups, albumin 
improved significantly at week 2 (p=0.039) and week 24 (p=0.030). In Amer et al study (117), 
albumin improved significantly (p<0.05) from week 2 which was maintained over the study 
period of 6 months. In Zhang Z study (133), albumin improved significantly in both MSC and 
SMT group from weeks 2 to weeks 36 when compared to baseline but there was no difference 
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between MSC and SMT at each time point. Two studies (125, 131) were able to combine the 
data for 2 weeks, 1, 3 and 6 months. Three studies (56, 97, 131) had 12 months albumin data 
and combined for analysis. It was shown that albumin improved more significantly in the SMT 
group at 1 month (MD: 2.40, 95% CI: 0.35-4.46, p=0.02), 3 months (MD: 4.00, 95% CI: 1.90-
6.10, p=0.0002) and 6 months (MD: 5.35, 95% CI: 2.74-7.96, p<0.0001) compared to MSC 
group but not at 12 months (MD: 0.78, 95% CI: -7.50, 9.06, p=0.85) (Figure 30).  
 
Figure 30: Albumin changes seen in chronic liver disease patients who had mesenchymal stem 
cell therapy (MSC) compared to standard medical therapy (SMT) at 2 weeks, 1 month, 3 
months, 6 months and 12 months of follow up 
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Suk et al study (97) data for ALP and GGT measurement pre-and post-therapy and for ALP 
showed that the MSC group had a greater reduction in ALP compared to SMT group (mean 
difference of -20 vs -3). However, there was no difference in GGT level between MSC and 
SMT groups at 12 months. Mohamadnejad et al study (56) mentioned that there was no 
difference in INR between MSC and SMT group at 12 months of FU and Amer et al study 
(117) showed similar outcomes in 6 months FU. Zheng et al study (132) mentioned that PT 
improved in both MSC and SMT groups at 1 months, 3 months and 12 months period but there 
was no difference between the two groups. In Zhang et al study (133), PT activity was improved 
significantly from weeks 2 to weeks 48 compared to baseline in both MSC and SMT group but 
there was no difference between them at any time point. In 3 studies (97, 125, 131), the data 
were able to be combined for analysis at different time points. INR improved significantly in 
MSC group at 3 months (MD: -0.26, 95% CI: -0.33, -0.19, p<0.00001), 6 months (MD: -0.28, 





Figure 31: International normalised ratio (INR) changes seen in chronic liver disease patients 
who had mesenchymal stem cell therapy (MSC) compared to standard medical therapy (SMT) 
at 2 weeks, 1 month, 3 months, 6 months and 12 months of follow up 
Child Pugh Score: Amer et al study (117) showed that Child Pugh score (CPS) improved in 
MSC group from 2 weeks till end of the study at 6 months but deteriorated in SMT group. In 
Zheng et al study (132), CPS improved in both MSC and SMT groups but there was no 
difference between the two groups (p>0.05). Salam et al study (125) mentioned that at the end 
of 6 months FU, 20% of MSC treated group had an improvement in CPS compared with 
baseline but not in the SMT group. Zekri et al (131) study showed that 40% had an 
improvement in their Child Pugh grade compared with the baseline in MSC group and the 
improvement occurred from 6 months onwards. Two studies (56, 97) had data for 12 months 
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FU that was able to be combined for analysis and it showed that CPS improved significantly 
with MSC therapy at 12 months (MD: -0.87, 95% CI: -1.55, -0.20, p=0.01) (Figure 32). 
 
Figure 32: Child Pugh score changes seen in chronic liver disease patients who had 
mesenchymal stem cell therapy (MSC) compared to standard medical therapy (SMT) at 12 
months of follow up 
Liver decompensation: Three studies (97, 131, 133) mentioned that there were no events of 
hepatocellular carcinoma occurring during the 12-month FU in MSC treated group. However, 
one study (131) mentioned that a focal lesion was found in the liver after 12 months of FU (1 
patient in MSC group compared to 2 patients in SMT). No events of sepsis were mentioned in 
any of the studies. There is only one study that gave MSC via the portal vein and the incidence 
of portal vein thrombosis was 3.3% (1 patient) in the MSC treated group compared to 6.7% (2 
patients) in SMT group (131). There were 4 studies (117, 125, 131, 133) that mentioned HE 
events although 2 studies (117, 133) reported that there was no significance between MSC and 
SMT group. However, two other studies (125, 131) showed that patients who received MSC 
had fewer episodes of HE at 3 months (OR: 0.26, 95% CI: 0.06- 1.21, p=0.09) and 6 months 
(OR=0.27, 95% CI: 0.07-1.04, p=0.06) post-treatment although they did not reach statistical 




Figure 33: Hepatic encephalopathy events in chronic liver disease patients who had 
mesenchymal stem cell therapy (MSC) compared to standard medical therapy (SMT) at 3 
months and 6 months of follow up 
Three studies (125, 131, 133) reported the event of gastrointestinal (GI) bleeding and in one 
study (133), there was no difference in the incidence of GI bleeding between MSC and SMT 
groups during 12 month of FU, whereas two other studies (125, 131)showed an improvement 
of GI bleeding in the MSC group. A second study (131) showed that the event of GI bleeding 
was 10% in the MSC group compared to 16.7% in SMT group at 12 months of FU. The other 
study (125) reported that there was a significant improvement in event of GI bleed in MSC 
group (100% at baseline to 0% at 3 months and 6 months) compared to SMT group (90% at 
baseline to 15% at 3 months and 16.7% at 6 months). Overall, there seemed to be a reduction 
of GI bleeding in MSC group compared to SMT group at 6 and 12 months.  
Four studies (117, 125, 131, 133) reported the development of ascites in MSC treated cohorts. 
These studies showed trends towards ascites improvement in MSC treated group compared to 




Table 17: Events of ascites seen in chronic liver disease patients who had mesenchymal stem 









6 Ascites improved from 2 weeks (p=0.001),1 month, 2 months and 4 
months.  




6 25% showed an improvement of the grade of ascites, as assessed by 




12 Ascites reduced at weeks 1, 2, 12, 36, 48.  




12 40% showed improvement in degree of ascites.  
60% showed no change in degree of ascites.  
None had deterioration in the degree of ascites at the end of FU. 
 
8.3.3: CLD and haematopoietic stem cell therapy (HSC) 
 
Study characteristics 
There were 6 RCT studies (82, 96, 123, 124, 126, 131), 6 non-RCT studies (61, 135, 137, 138, 
141, 143), 2 controlled studies (106, 141) and 10 non-controlled studies for HSC therapies (53, 
85, 96, 167, 174, 180, 183, 187, 196, 197). All RCT studies were included in the final 
quantitative and qualitative analysis. There was a non-RCT study that was presented as a 
conference abstract (205) with 5-year outcome data and therefore, included in the analysis due 
to longer duration of FU.   
In five studies  (82, 124, 126, 131, 143), subcutaneous GCSF injection was used to mobilise 
cells from the one marrow and the dose of GCSF varied in each study. In 2 studies (126, 131) 
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cells were aspirated directly from the bone marrow after giving GCSF but in the other 3 studies 
(82, 124, 143) they were collected from peripheral blood after GCSF injection. In two studies, 
the dose of GCSF was 300 ug/day for 5 days (126, 131) but in other studies, the investigator 
had used 15 ug/kg/day for 5 days (82) or 10 ug/kg/day for 5 days respectively (143). In other 
two RCT studies (96, 123) GCSF was not used and HSC was collected directly from the bone 
marrow. 
Two studies (126, 131) used both CD133+/CD34+ cells, other 3 studies used CD133+ cells 
only (82, 96, 123) and 2 other studies (124, 143) used CD34+ cells only.  
Primary outcomes 
Overall patient survival: Three studies (82, 126, 131) had 12-month mortality data and one 
study (205) had 5-year mortality data. From the meta-analysis, it seemed that patients who had 
HSC therapy did not have improved survival outcomes compared to the control group at 12 
months (OR=0.34, 95 % CI: 0.07, 1.58, p=0.17) and 5 years (OR=0.32, 95 % CI: 0.10, 1.07, 




Figure 34: Overall patient survival in chronic liver disease patients who had haematopoietic 
stem cell therapy (HSC) compared to standard medical therapy (SMT) at 12 months and 5 years 
of follow up 
 
LT free survival: Three studies (82, 96, 124) mentioned 12-month LT-free survival data which 
showed that patients who received HSC therapy were no less likely to receive LT compared to 
SMT group at 12 months (OR: 0.26, 95% CI: 0.05, 1.41, p=0.12) (Figure 35).  
 
Figure 35: Liver transplant free survival in chronic liver disease patients who had 
haematopoietic stem cell therapy (HSC) compared to standard medical therapy (SMT) at 12 
months of follow up 
MELD:  In three studies (96, 131, 143), data were able to be combined and there was a 
significant improvement of MELD seen in the HSC treated group at 3 months (MD: -2.12, 95% 
CI: -3.3, -0.93, p=0.0005) but this was not seen at 6 months compared to SMT group (MD: -
0.54, 95% CI: -3.53, 2.44, p=0.72) (Figure 36). In Newsome et al (82), there was no difference 
in MELD score at baseline, days 90 and days 180 in both HSC and SMT treated groups. One 
study (205) had MELD data up to 5 years in HSC group and the mean difference of MELD 




Figure 36: Model for End Stage Liver Disease (MELD) changes in chronic liver disease 
patients who had haematopoietic stem cell therapy (HSC) compared to standard medical 
therapy (SMT) at 3 months and 6 months of follow up 
QoL: Three studies (82, 126, 143) mentioned the impact of HSC therapy on patients’ QoL. 
Newsome et al (82) showed similar change in QoL in both HSC and SMT groups when 
compared at baseline and day 90. However, Nakamura et al mentioned that HSC therapy 
improved all sections of QoL especially in social role functioning at 24 weeks (143).  In Salama 
et al (126), the performance scale was improved in HSC treated group compared to SMT group 
(at 6 months: 75% of HSC group had score 0 compared to 5% in SMT group).   
Adverse events to intervention: Most of the adverse events are related to GCSF and the common 
events recorded were low grade fever (123, 126, 131, 143) and bone pain (126, 131, 143). 
There were no complications reported with stem cell infusion in any of the studies. In 4 studies 
(96, 123, 126, 131), the cells were given via portal vein and according to analysis, the incidence 
of portal vein thrombosis was similar between HSC and SMT group (OR=0.96, 95% CI: 0.13, 




Figure 37: Incidence of portal vein thrombosis in chronic liver disease patients who had 
haematopoietic stem cell therapy (HSC) compared to standard medical therapy (SMT) 
Secondary outcomes 
Liver function tests: In a study by Newsome et al (82), both ALT and AST improved at 1 and 
3 months compared to baseline in both HSC and SMT groups although there was no difference 
between the two groups at any time point. Two studies (96, 126) had ALT and AST data for 3 
months and 6 months. For ALT, there was an improvement at 3 months for HSC group (MD: 
-18.89, 95% CI: -34.26, -3.53, p=0.02) although that was not seen at 6 months (MD: 6.48, 95% 
CI: -27.52, 40.49, p=0.71) (Figure 38a). For AST, the improvement was not seen either at 3 
months (MD: 7.52, 95% CI: -46.22, 61.29, p=0.78) or 6 months (MD: -8.51, 95% CI: -17.25, 




Figure 38: Liver enzyme changes (ALT: Alanine transaminase and AST: Aspartate 
transaminase) seen in chronic liver disease patients who had haematopoietic stem cell therapy 
(HSC) compared to standard medical therapy (SMT) at 3 months and 6 months of follow up 
Two studies (126, 131) had bilirubin data at 1 and 2 months and for 3 and 6 months. There 
were 3 studies (96, 126, 131) able to be combined for meta-analysis. Bilirubin level was 
improved significantly in HSC group at 6 months (MD: -12.70, 95% CI: -23.78, -1.62, p=0.02) 
but not at 1 month (MD: -1.24, 95% CI: -5.9, 3.42, p=0.60), 2 months (MD: -5.23, 95% CI: -
10.74, 0.28, p=0.06) or 3 months (MD: -7.79, 95% CI: -16.5, 0.92, p=0.08) (Figure 39). Zekri 
et al study (131) had 9 months and 12 months data for bilirubin but did not show any difference 
between HSC and SMT groups. Newsome et al (82) had bilirubin data for days 90 and 180 but 
139 
 
there was no difference between the two groups. Nakamura T study (143) had bilirubin data up 
to 6 months and did not show any difference between the two groups.  
 
Figure 39: Bilirubin changes seen in chronic liver disease patients who had haematopoietic 
stem cell therapy (HSC) compared to standard medical therapy (SMT) at 1 month, 2 months, 
3 months and 6 months of follow up 
A study by Nakamura et al (143) showed that serum albumin level at 24 weeks was not changed 
in either HSC or SMT treated groups compared to baseline. Another study (82) mentioned that 
there was no difference in albumin level in days 30 and 90 in both HSC and SMT group. In 
Raju et al (124), 93% of patients showed improvement in albumin during 12 months of FU. In 
3 studies that was combined for data analysis (96, 126, 131), albumin level was significantly 
improved in SMT group at 3 months (MD: 3.25, 95% CI: 1.00, 5.51, p=0.005) but became 
similar between the two groups at 6 months (MD: 3.14, 95% CI: -0.63, 6.92, p=0.10) (Figure 
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40).  Overall, albumin was improved better in SMT group compared to HSC group (OR= 3.28, 
95% CI: 1.26, 5.31, p=0.001).  
 
Figure 40: Albumin changes seen in chronic liver disease patients who had haematopoietic 
stem cell therapy (HSC) compared to standard medical therapy (SMT) at 3 months and 6 
months of follow up 
A study by Raju B et al (124) mentioned that 68% of patients had improvement in INR during 
12 months FU but in another study by Newsome et al (82), there was no difference in change 
between HSC and SMT group at days 30 and 90 compared to baseline. In Salama et al (126), 
prothrombin concentration (PC) percentage was measured and HSC group had significantly 
improved PC% at 1, 2, 3 and 6 months after HSC therapy. Another study (143) did not show 
any change in INR between HSC and SMT treated groups. In two studies (96, 131), INR 
seemed to improve at 3 months with HSC therapy (MD: -0.24, 95% CI: -0.34, -0.14, 
p<0.00001) but not at 6 months post-treatment (MD: -0.17, 95% CI: -0.38, 0.04, p=0.12) 




Figure 41: International normalised ratio (INR) changes seen in chronic liver disease patients 
who had haematopoietic stem cell therapy (HSC) compared to standard medical therapy (SMT) 
at 3 months and 6 months of follow up 
Child Pugh Score: Four studies (82, 126, 131, 143) reported Child Pugh Score (CPS) but due 
to variation in reporting, the data were not able to be combined for meta-analysis. In Zekri et 
al (131), 40% of patients that received 2 injections of HSC had an improvement in CPS 
compared to baseline (p<0.05) during 12 months FU and the maximum benefit was noted from 
6 months onwards after therapy. Another study (126) also mentioned that the maximum 
improvement of CPS occurred after 6 months. In Newsome et al (82), there was difference in 
CPS at days 30 and 90 in both HSC and SMT groups.  In Nakamura et al (143), HSC treated 
group had maintenance and/or improvement in CPS compared to control during 24 months of 
FU although it did not reach statistical significance.  
Liver decompensation events: There were no cases of malignancies reported in any of the 
studies within 12 months (82, 126, 131) as well as 24 months of FU (143). Nakamura et al 
(205) reported the incidence of HCC within 5-year FU and showed similar rates between HSC 
and SMT groups (44.4% vs 42.9%).  The incidence of variceal bleeds was similar between 
HSC and SMT group in one study (131) although in another study, there was an improvement 
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of GI bleed in HSC group over SMT group over 6 months FU (126) . Hepatic encephalopathy 
incidence was similar between the HSC and SMT groups in one study over 12 month FU (131). 
However, study by Salama et al (126) showed improvement of HE in HSC treated group 
compared to SMT over 6 months FU.  Overall, it appeared that ascites improved with HSC 
therapy. One study showed that there was a 40% improvement of ascites in HSC treated group 
at the end of 12 month FU (131). In another study (124), there was less frequency of 
paracentesis and required lower dose of diuretic use to control ascites in HSC group and in 
third study (126), it showed that the maximum improvement of ascites was found after 6 
months in 63.6% of HSC treated groups.  
8.3.4: CLD and Bone marrow stem cell (BMSC) 
 
Study characteristics 
Any studies with unspecific stem cells types but received directly from the bone marrow as 
well as peripheral blood stem cells that had been mobilised with GCSF from bone marrow were 
included. There were 6 RCT studies (119, 121, 122, 127, 130, 150), 6 non-RCT studies (134, 
136, 140, 145, 148, 149), 5 controlled studies (107, 108, 110, 150, 152) and 20 non-controlled 
studies (153, 157, 161-163, 171, 175, 178, 179, 181, 184, 186, 188-190, 193, 195, 198, 200, 
206). RCT studies had 12 months duration of FU (119, 122) but in 2 non-RCT studies (134, 
149) that had longer duration of FU at 24 months and they were also included in final 
quantitative and qualitative analysis.  
In three studies (121, 127, 130), GCSF was used to mobilise stem cells and the dose varied in 
each study: 5 micrograms per kg per day for 3 days (130), 10 ug/kg/day for 5 days (127) and 
100 ug for one day (121). Cells were obtained directly from bone marrow in 6 studies (119, 
121, 122, 127, 134, 149), from peripheral blood in one study (130) and unknown in the other 
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study (150). Hepatic artery was used to deliver the cells in 7 studies (119, 121, 122, 127, 134, 
149, 150) and portal vein was used in the other study (130).  
Primary outcomes 
Overall patient survival: In a study by Lyra et al (122), 3 patients from the BMSC group died 
compared to 2 patients from the SMT group during 12 months FU (20% vs 13.3%) and in 
another study, 2 patients from BMSC died compared to 4 patients from SMT group during 3 
months FU (7% vs 13.3%).  
LT free survival: In one study (122) a patient from the BMSC group underwent liver 
transplantation 45 days after randomisation due to progressive liver disease but no data were 
available on SMT group.  
MELD: Three studies (122, 127, 130) reported the outcome of MELD and in 2 studies (122, 
127) the data were able to be combined in the first 3 months post-therapy. From these studies, 
despite the improvement in MELD score in BMSC, the difference was similar when compared 
to the control group at 1 month (MD: 0.33, 95% CI: -1.43, 2.08, p=0.71), 2 months (MD: 0.21, 
95% CI: -1.22, 1.63, p=0.77) and 3 months (MD: 0.41, 95% CI: -1.75, 2.56, p=0.71) (Figure 
42). Yu et al (130) mentioned that there was no difference in MELD between BMSC and SMT 
group. Lyra et al reported (122) MELD outcomes in 1, 2, 3, 6 and 12 months and in this study 
MELD score remained stable in the treated patients with mean relative changes (RC) from -
2% at 2 months to +6% at 12 months compared to control group with mean RC +6% at 2 
months to +18% at 12 months. Despite these changes, when comparing the slope between the 
BMSC and control group at 3 months and 12 months there was no statistical significance. In a 
study from Spahr et al (127), 68% of patients from BMSC achieved a decrease of more than 3 




Figure 42: Model for End Stage Liver Disease (MELD) changes seen in chronic liver disease 
patient who had bone marrow stem cell (BMSC) therapy compared to standard medical therapy 
(SMT) at 1 month, 2 months and 3 months of follow up 
QoL: Not many studies had reported QoL data except one study that mentioned degree of 
fatigue before and after treatment. In that study (121), more patients in BMSC group had 
improvement in fatigue score with 21 patients having less symptoms of fatigue in the BMSC 
group compared to 7 patients in the SMT group (52.5% vs 18.9%).  
Adverse events to intervention: In 3 studies (119, 149, 150) no serious complications were 
reported in patients that received BMSC. GCSF therapy was well tolerated and only one patient 
experienced low grade fever  (121). There were no reports of splenic rupture recorded due to 
GCSF as well as no event of PVT in patients who received cell therapy via the portal vein 
(130). Mild pain at the puncture site and haematoma at puncture site was noted in patients who 





Liver function tests: A study showed that there were no changes in ALT over 12 months FU 
(119). In another study (121), there was an improvement in both ALT and AST at 4 weeks in 
both BMSC and control compared to baseline as well as BMSC compared to SMT (BMSC: 
ALT baseline 75.1 ± 19.8 vs 4 weeks 35.2 ± 12.5 vs Control: ALT baseline 72.3 ± 21.5 vs 4 
weeks 52.7 ± 13.4). Zhao et al (149) reported that AST improved in cell therapy group at both 
6 months (p=0.034) and 12 months (p=0.05).  
Regarding bilirubin, there was no improvement in bilirubin level at 52 weeks in BMSC group 
(baseline: 50.4 +/- 6.0 vs at 52 weeks: 41.52 +/- 8.55) (119). The data were able to be combined 
for 1, 3, 6 and 12 months duration in some studies (121, 122, 134) and presented in meat-
analysis format. There was a significant improvement of bilirubin in BMSC groups at 1 month 
(MD: -8.73, 95% CI: -13.31, -4.15, p=0.0002), 6 months (MD: -10.56, 95% CI: -19.81, -1.30, 




Figure 43: Bilirubin changes seen in chronic liver disease patient who had bone marrow stem 
cell (BMSC) therapy compared to standard medical therapy (SMT) at 1 month, 3 months and 
6 months of follow up 
One study found that albumin level improved at 4 weeks and 52 weeks with BMSC therapy 
compared to baseline, but no data was available to compare with SMT (119). In another study, 
albumin level improvement significantly at 6, 12 and 24 months post cell therapy (p=0.046, 
0.033, 0.024) respectively (149). From the studies (121, 122, 134), BMSC therapy did not 
improve albumin at either 1 month (MD: 0.56, 95% CI: -2.21, 3.33, p=0.69), 3 months (MD: 
0.11, 95% CI: -6.58, 6.80, p=0.97), 6 months (MD: 0.21, 95% CI: -6.79, 7.22, p=0.95) or 12 
months (MD: 0.78, 95% CI: -7.50, 9.06, p=0.85) (Figure 44). 
 
Figure 44: Albumin changes seen in chronic liver disease patient who had bone marrow stem 
cell (BMSC) therapy compared to standard medical therapy (SMT) at 1 month, 3 months, 6 




There was no difference in INR between BMSC and SMT group at 1, 2, 3, 6, 12 and 24 month 
in one study (122) but in another study (134), there was an improvement of PT at 3 months 
(p=0.046), 6 months post therapy (p=0.019) but not at 12 or 24 months.  
Child Pugh Score: Three studies (119, 122, 149) had outcomes for Child Pugh Score. Huang 
et al mentioned that there was a reduction in CPS in both BMSC and control group (mean 
reduction of -0.8 in BMSC vs -2.8 in SMT group at 52 weeks) and in SMT group, there was a 
statistical difference in CPS compared to baseline (p<0.05) but not in the BMSC group. In Lyra 
A et al (122), CPS improved in the first 3 months in BMSC group compared to controls with 
mean RC of -8% in BMSC vs +5% in control group (p=0.017) but not maintained in 6 months 
or 12 months data. In another study (149), there was a significant improvement in CPS at 6, 12 
and 24 months (p=0.001, 0.046, 0.003) respectively.  
Liver decompensation events: Only one study reported that there was no event of HRS or HE 
in BMSC treated group (130) and 3 studies reported no event of hepatocellular carcinoma in 
the cell therapy group (122, 127, 130). There were no events of GI bleeding reported. (119, 
130). Three studies reported that there was an improvement in ascites within 4 weeks in BMSC 
treated groups compared to SMT (119, 121, 150). Rates of infection reported were similar 
between the BMSC and SMT treated groups (127, 130, 134).  
8.3 (ii): Acute-on-Chronic liver failure (ACLF) 
 
Study characteristics 
There were 6 RCT studies (57, 69, 207-210), 2 controlled studies (115, 116) and 2 non-
controlled studies (211, 212). The longest duration of follow-up from RCT study was 12 
months but it was a conference abstract study and only had limited information (209). 
Therefore, a controlled study with 12 to 18 months follow up was included in the analysis 
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(115). Other controlled and non-controlled studies had similar follow up duration to RCT 
studies and hence, were not included in the quantitative analysis.  
Finally, six RCT studies (57, 69, 207-210) and one controlled study (115) were reviewed for 
both primary and secondary outcomes. In RCT, 2 studies examined the effect of BM-MSC (57, 
207) and 4 studies looked at the effect of GCSF (69, 208-210, 213). Khanam et al 2014 (213) 
shared the same patient population cohort with Garg V et al (210) and therefore, results from 
Khanam et al paper were combined with Garg et al. In patients who received MSC therapy, 
they received them through peripheral vein and all had hepatitis B related liver disease. A 
controlled study examined the effect of UC-MSC (115) and for quantitative analysis, both BM-
MSC and UC-MSC were grouped together. In studies with GCSF therapy, the dose varied from 
each study and they were given subcutaneously as follows: 5 ug/kg/day for 6 days (208), 5 
ug/kg/day for 5 days and every 3rd day until day 26 (209), 5ug/kg twice daily for 5 days (69) 
and 5 ug/kg once daily for 5 days and every 3rd day for total of 12 doses (210). The details of 
the included studies were documented in Table 18 and appendix 8.
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Table 18: Summary of the included studies (Acute-on-chronic liver failure) 
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Overall patient mortality: Two studies (57, 115) with MSC therapy had survival outcome data 
although their study design and FU duration were dissimilar and hence they were unable to be 
combined. In Lin et al study (57), the survival rate in MSC group was 73.2% compared to 
55.6% in SMT group for 6 months FU. In Shi M 2012 study (115), the survival rate in MSC 
group was 87.5% compared to 89.5% in SMT at 18 months FU.  
Three RCT studies with GCSF therapy had patient survival outcome data during 3 months of 
FU and hence, the data were combined (69, 208, 210). The analyses showed that patients with 
ACLF who received GCSF therapy tended to have significantly improved survival outcome at 
3 months (OR=0.16, 95% CI: 0.08, 0.34, p<0.00001) (Figure 45). The causes of death in each 
study were shown in Table 19. Most patients died from sepsis and multi-organ failure.   
 
Figure 45: Overall patient survival of patients with acute on chronic liver failure (ACLF) who 
had granulocyte colony stimulating factor (GCSF) compared to standard medical therapy 





Table 19: Causes of death reported in patients with acute on chronic liver failure (ACLF) who 
had granulocyte colony stimulating factor (GCSF) 
 
Liver transplant free survival: None of the studies reviewed the effect of stem cell on liver 
transplant free survival.  
MELD: Three studies of MSC (57, 115, 207) and GCSF (69, 208, 210) therapies reported 
MELD data. However, the data were not suitable to combine for meta-analysis due to 
differences in statistical method and follow up time frame. Therefore, the data were presented 
in Table 20. In studies with MSC therapy, one study (57) showed improvement of MELD in 
week 1 and 2 after therapy and other studies (115, 207) showed improvement from week 4 to 
week 12.  
In GCSF groups, there is improvement of MELD within 4 weeks in 2 studies (69, 208). In 
GCSF treated patients, one study showed improvement of MELD at week 1 and 2 (208) and 2 
studies (69, 208) showed improvement of MELD at  week 4. 
Table 20: Model of end stage liver disease (MELD) changes seen in acute on chronic liver 
failure (ACLF) who had granulocyte colony stimulating factor (GCSF) at baseline, 1 week, 2 
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N=15 Severe infection 
(n=18) 
Hepatic coma (n=7) 
HRS (n=10) 
GI bleed (n=2) 
MOF (n=20) 
N=24 Severe infection (n=9) 
Hepatic coma (n=4) 
HRS (n=5) 




RCT GCSF N=14 Hepatic 
encephalopathy 
(n=4) 














SBP, sepsis and 
renal failure (n=2) 
N=18 GI bleed, pneumonia, 
sepsis and HRS (n=3) 
Pneumonia, sepsis 
and HRS (n=5) 
Urine infection and 
renal failure (n=3) 




RCT GCSF N=7 Liver failure (n=2) 
MOF (n=3) 
GI bleed (n=2) 
N=17 Liver failure (n=1) 
MOF (n=12) 





weeks, 3 weeks, 1 month, 3 months and 6 months of follow up when compared to standard 
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p<0.001 
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GCSF Median  27  24    p=0.05   p=0.078  














SMT  31.5 
(20-40) 








Quality of life (QoL): None of the studies reported QoL in ACLF patients who received cell 
therapies.  
Adverse events to intervention: In patients who received MSC therapy, one study (57) 
mentioned that 15 patients from MSC group had fever compared to 12 patients in control group 
within first 4 weeks of infusion which had increased significantly in 5 to 24 weeks post infusion 
period (n=10 in MSC group vs n=1 in SMT group, p=0.02). This study also showed that 8 
patients had rash in MSC group compared to 7 patients in control group as well as 7 patients 
in each group had diarrhoea. Another study from Shi et al also mentioned that two patients who 
received MSC infusion developed fever within 2 to 6 hours of infusion and resolved within 12 
hours of infusions but none in the control group developed fever (115).  
Three studies (69, 208, 210) reported the adverse events secondary to GCSF injection and 
among these 3 studies, low grade fever (n=9), headache (n=7), nausea (n=4), bone pain (n=3), 
rash (n=1) and herpes zoster infection (n=1) were found in patients who received GCSF 
therapy.  
Secondary outcomes 
Liver function tests: The data were expressed differently in each study which made it not 
possible to combine the data together for analysis. In the MSC treated group, there was an 
significant improvement of ALT during week 1 (57, 207) and week 2 (207) compared to 
baseline although in another study (115), there was an significant improvement in week 8 and 
48 weeks post-MSC therapy compared to SMT group. There was no improvement of bilirubin 
level in MSC treated group in one study within 24 weeks FU (57) but in another study, it 
showed significant improvement in the MSC group compared to SMT group at week 36 and 
48 (115). Albumin level was significantly improved 1 week after MSC therapy in one study 
(57) but in another study, it showed improvement in MSC group at week 12, 24, 36 and 48 
weeks compared to SMT group (115). INR improved significantly in week 2 and 4 after MSC 
therapy (207) but in another study, it improved at week 1, 2, 4, 36 and 48 weeks after MSC 
therapy compared to SMT group (115).  
In GCSF treated groups, no data were available for ALT and albumin changes. One study 
showed that bilirubin was improved significantly compared to baseline in GCSF treated group 
in week 4 and 8 post therapy (210). One study (210) documented the change in INR within 8 
weeks of GCSF therapy but there was no difference noted with therapy. 
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Child Pugh Score: None of the MSC studies had outcomes for Child Pugh score.  
One study of GCSF showed a significant improvement of CPS in GCSF group compared to 
control group (208). In Singh et al paper (69), there was a significant reduction in median delta 
change percentage in CPS at 1, 2 and 3 months post GCSF (p<0.05). Another study from Garg 
et al (210) showed that there was a significant median change CPS improvement at days 7, 30 
and 60 in GCSF treated group.  
Events of liver decompensation: For MSC treated group, only one study (57) mentioned liver 
decompensation events and it showed that patients who had MSC therapy experienced less 
liver decompensation events compared to the control group: MSC group had hepatic 
encephalopathy (n=8), gastrointestinal bleed (n=1), HRS (n=6) and infection (n=14) compared 
to control group whom had hepatic encephalopathy (n=14), gastrointestinal bleed (n=3), HRS 
(n=12) and infection (n= 24). No one developed hepatocellular carcinoma in that study.   
For studies with GCSF therapy, one study (69) showed that there was a significant reduction 
of ascites in GCSF group compared to control group (p=0.047) at 3 months FU. Two studies 
(208, 210) reported the event of hepatic encephalopathy (HE), sepsis and hepatorenal syndrome 
(HRS) and all patients who received GCSF had significantly less episodes of sepsis (OR=0.28, 
95% CI: 0.10, 0.79, p=0.02) and HRS (OR=0.14, 95% CI: 0.04, 0.47, p=0.001) compared to 
control group over 2-3 months FU but not in event of HE (OR=0.26, 95% CI: 0.004, 1.51, 




Figure 46 (A-D): Hepatic decompensation events in patients with acute on chronic liver failure 
who had granulocyte colony stimulating factor (GCSF) compared to standard medical therapy 
(SMT): A: Hepatic encephalopathy event, B: Sepsis, C: Hepatorenal syndrome, D: 
Gastrointestinal bleeding 
8.4: Subgroup analysis 
 
Subgroup analysis were planned based on cell administration route (central vs peripheral) or 
the source of stem cell (autologous vs allogenic) for each population (CLD and ACLF) and 
each cell types (as in MSC, HSC, BMSC and GCSF). However, the analyses were not 
performed due to smaller number of studies when grouping them together with significant 
heterogeneity among studies.  
8.5: Discussion  
 
The current systematic review and meta-analysis aimed to analyse the clinical effectiveness of 
stem cell therapies in patients with CLD and ACLF. The stem cells of interest were HSC, MSC, 
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BMSC and GCSF and the outcomes interested were mortality of patients, clinical 
improvements assessed by QoL, MELD, CPS, biochemical blood tests as well as the safety 
profile of cell therapies.  
8.5 (i): Chronic liver disease 
 
This systematic review showed that GCSF therapy significantly improved mortality at 3 for 
ACLF and 6 months for CLD post therapy although in our clinical study (82), GCSF did not 
improve survival of patients compared to either SMT or HSC group. There was no difference 
in survival found between MSC and SMT group for 12 months FU duration. HSC did not 
improve survival at 12 months and at 5 years FU when compared to SMT. Moreover, no other 
cell therapies seemed to improve overall patient survival compared to SMT. Regarding GCSF, 
HSC and BMSC treated groups, there were no significant differences in LT survival rate when 
compared to SMT group. There were no data available for LT survival in MSC treated group.  
There were significant variations in the reporting of MELD. MELD improved at 6 months in 
one study (120) but not in 2 other studies (82, 130) when treated with GCSF. MELD 
significantly improved in MSC treated group at 3 and 6 months but not in 12 months. MELD 
improved in HSC treated group at 6 months in the systematic review but not in longer term 
follow up at 12 months or even at 5 years. In our clinical study (82), MELD was not improved 
in any of the study group. In patients who had BMSC treatment, MELD did not improve either 
in short term (3 months) or long term (12 months) follow up period. From these studies, all cell 
therapies (GCSF, MSC and HSC) MELD seemed to improve at shorter term (up to 6 months) 
but not in longer term.  
QoL data was sparse amongst studies. Newsome et al (82) measured QoL in GCSF treated 
group but there was no significant improvement at 3 months when compared with SMT. 
Studies from MSC (117) and HSC (126, 143) showed improvement in fatigue and performance 
score at 6 months. BMSC treated group also had improvement in fatigue score at 4 weeks post 
treatment (121). All cell therapies had a good safety profile with no significant event of portal 
vein thrombosis compared to SMT. Fever is a common side effects seen in patients that had 
treatment with GCSF or MSC therapies.  
Child Pugh score was improved significantly with GCSF therapy up to 6 months post treatment, 
but we did not find improvement of CPS in our clinical study (82). There was an improvement 
of CPS at 6 and 12 months for MSC treated group. No difference in improvement was noted 
for HSC treated group either at 12 or 124 months of FU.  
159 
 
Liver cancer incidence did not increase with cell therapies (GCSF, MSC, HSC or BMSC). 
Events of HRS were similar between cell treated groups (GCSF or BMSC) and SMT group. 
SBP was similar between GCSF and SMT. Sepsis rate was lower in GCSF group, but no 
difference was found in BMSC group compared to SMT. There was no difference in event of 
HE between cell therapies (GCSF, MSC, HSC and BMSC) and SMT groups. Ascites seemed 
to improve in all cell therapies (GCSF, MSC, HSC and BMSC) between 6 and 12 months 
duration. There seemed to be reduction of GI bleed in either MSC, HSC of BMSC treated 
groups. In patients that received stem cells through portal vein, the incidence of portal vein 
thrombosis was similar between stem cell and SMT groups. 
8.5 (ii): Acute on chronic liver failure 
 
Similar survival outcome was found between MSC and SMT group. However, GCSF therapy 
significantly improved survival at 3 months compared to SMT. No studies reported LT free 
survival. There was an improvement towards MELD in both MSC and GCSF treated group 
compared to SMT group in short term FU (up to 4 weeks) but unable to combine data for 
analysis. No QoL data available from any of the studies.  
Fever was common in both MSC and GCSF treated cohorts, but no other serious events were 
documented. There was no significant change in ALT, bilirubin for MSC treated group but 
albumin and INR showed some improvement at 48 weeks FU. There were no data available 
for albumin and ALT in GCSF treated groups, but bilirubin improved at 8 weeks post therapy, 
but they were not significant compared to SMT. MSC treated group had no data for CPS and 
in GCSF, two studies (69, 210) showed improvement of CPS at 3 months. MSC treated groups 
had lesser events of liver decompensation compared to SMT. GCSF improved ascites at 3 
months with less patients developed sepsis, HRS but no difference was found in GI bleed event. 
No HCC was documented in cell therapy group.  
8.5 (iii): Strength of the study 
 
There were many strengths in this study. This is the only study so far with most recent literature 
searches up to 2017 with the largest numbers of included randomised controlled trials. Prior to 
starting this review, a well thought out protocol was written in regard to population, 
interventions, outcomes and study that we were interested to review. The plan on how to handle 
the data and how to analyse were clearly thought out and written in the protocol paper before 
starting. The eligibility criteria for the study population was clear in that we excluded patients 
who had liver surgery or had underlying liver cancer.  
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8.5 (iv): Limitations of the study 
 
There were several limitations. Although we aim to include non-English studies, due to time 
constraint, we were unable to translate non-English papers. However, for RCT, there were only 
2 papers in Chinese language that did not include in analysis and it is unlikely to make 
significant difference in the outcomes of the studies. Although the searches were done as 
comprehensive as possible, it might not be enough to cover all related references. To remove 
irrelevant articles, one reviewer screened all the titles and abstracts and to ensure consistency, 
another reviewer checked a proportion (minimum 50% of all articles) independently. This way 
of screening articles was a limitation of the study due to this project being unfunded. 
The analyses were performed according to cell types, types of liver disease and study design 
although there was still significant heterogeneity in the aetiologies of liver diseases. We were 
unable to do subgroup analysis on type of liver disease or route of stem cell administration due 
to limited number of studies as well as heterogeneity across the studies. Regarding performing 
meta-analysis, there was variations in the statistical methods that data was presented and the 
time frame that the data was collected which makes the direct comparison difficult. That leads 
to inherent weakness in combing heterogeneous data sets at time although we tried to limit this 
variation by combining similar cell types and study design using the random effect model 
although it might not still eliminate the effect of heterogeneity.  
Due to limitations with availability of data, the source of the stem cells was not differentiated 
(as in bone marrow-MSC vs umbilical cord-MSC). Although sub-group analyses were planned, 
the number of studies when breaking down into each category became small that any 
meaningful outcomes could not derived from the analyses.  
From these studies, we were unable to report on the optimal dose and duration of GCSF therapy 
due to significant variations across studies. With that, the benefits of the therapy may be sub-




9. OVERALL DISCUSSION 
 
Incidence and the mortality associated with chronic liver disease is rising and the only curative 
modality is liver transplantation. Due to increased demand but stable organ donation rate, some 
patients die while waiting on the list for organ. Stem cell therapies had been promising and 
over the past decade, various types of stem cells in various form of liver diseases had been 
studied either in animal or human. Most animal studies showed improvement of liver fibrosis 
after stem cell therapy (218-220).  
As part of the thesis, I worked on the previous animal project completed by one the researcher 
in our unit. The CCl4 chronic liver injury mice model was given repeated infusion of HSC cells. 
I worked on the response of oval cell reaction by staining liver tissue with pan-CK and Sox-9 
staining. Pan-CK staining was significant higher in the livers of KSL treated mice although 
Sox-9 staining was similar between KSL treated and control mice. The probable reason for this 
difference is that Sox-9+ cells likely only contribute a minor response towards hepatic 
regeneration process. This is supported by the study from Tarlow et al which showed Sox9+ 
ductal proliferation makes only a minor contribution to parenchymal regeneration in liver 
injuries (81). KSL treated mice had significantly higher levels of MMP-9 and 12 compared to 
control which potentially increased the process of breaking down fibrosis in ECM remodelling. 
For qPCR analysis, MMP-9 was significantly higher in KSL treated mice but not for other 
MMPs (2,8,12 and 13). Individual macrophage markers (iNOS and Arg-1) were similar 
between the two groups although the Arg-1/NOS-2 ratio was significantly lower in KSL treated 
mice indicating a change in the fibrotic milieu. Due to the benefit of repeated stem cell 
infusions in animal mode, we proceeded to a phase II clinical trial. It was a multi-central open 
label randomised study and we recruited 81 patients in total. They were randomised to 3 groups: 
standard care, GCSF only and GCSF and stem cell (CD133+) infusion group. The trial primary 
outcome was change of delta MELD in day 90 from day 1 (at randomisation). There was no 
significant improvement of MELD in all 3 groups. All the other secondary outcomes were not 
significant either. Our study finding contrasted with many clinical trials (96, 110, 114, 221) 
that had been performed and published with improvement in function of the liver. Therefore, a 
systematic review was conducted to analyse whether stem cell therapies was effective 
treatment in patients with liver diseases. We examined all types of stem cells (HSC, MSC, 
BMSC and GCSF) in patients with CLD or ACLF. The systematic review showed that GCSF 
therapy significantly improved mortality at 3 months for ACLF patients and 6 months for CLD 
patients although we did not find similar finding in our clinical trial (82). There was no 
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difference in LT free survival between any stem cell therapies and standard medical therapy 
groups. MELD improved significantly in MSC treated groups at 3 and 6 months but not with 
any other cells. Albumin improved in MSC group up to 6 months and for HSC, the 
improvement is only up to 3 months. Bilirubin improved at 6 months for all cell types (HSC, 
MSC, BMSC) except GCSF group.  INR was significantly improved in MSC treated group at 
3, 6 and 12 months but only improved at 3 months for HSC group. 
In our trial (82), neither GCSF nor HSC infusion improve overall survival, MELD score, CPS, 
QoL or clinical blood parameters compared to SMT. For GCSF, our study was dissimilar to 
systematic review because in systematic review, GCSF improved patient survival at 6 months 
compared to SMT but not in longer term at 12 months. More studies are required to understand 
the effect of GCSF therapy in patients with liver diseases.  For HSC infusion, neither mortality, 
MELD or liver enzymes were improved in both our trial and in systematic review. 
10: CONCLUSION 
 
Stem cells showed degree of improvement in biochemical markers, MELD and CPS only for 
shorter duration (<6 months). We needed well designed, adequately powered, robust 
randomised studies with longer duration of follow up (more than 12 months) and large number 
of patients. We will need to have studies with more robust clinical outcomes to examine the 
clinical efficacy of stem cell therapy. I do not think that change sin MELD or Fibroscan may 
not be a good clinical end outcome. We need to have significant changes in these findings to 
interpret meaningfully in clinical settings. We may need to consider other means to determine 
the progression of fibrosis such as spleen stiffness measurement or performing hepatic venous 
pressure gradient (HVPG) measurement. We also need to perform in-vivo tracking of stem cells 
to examine the clinical effectiveness of stem cell therapies in patients with liver diseases.  
In summary, stem cells therapy in liver cirrhosis is still an emerging filed and need better 
understanding on pathogenesis of liver fibrosis and how stem cells can improve the fibrosis. 
Further robust randomised clinical trials are before stem cells can be used in daily clinical 









Appendix 1: Chronic liver disease questionnaire (CLDQ)  
 
General Patient trial number 
Date of questionnaire 
Assessment: Day 1 (screening)  
Day 90 (visit 5)     
Day 180 (visit 6)     
Day 360 (visit 7) 
This questionnaire is designed to find out how you have been feeling during the last two 
weeks.  
You will be asked about your symptoms related to your liver disease, how you have been 
affected in doing activities, and how your mood has been.  
Please complete all of the questions and select only one response for each question.  
The answer should be selected from one of 
the following choices for any given 
questions. 
1. All of the time 
2. Most of the time 
3. A good bit of the time 
4. Some of the time 
5. A little of the time 
6. Hardly any of the time 
7. None of the time 
 How much of the time during the last 2 
weeks...?? 
Question 1 Have you been troubled by a feeling of 
abdominal bloating?  
Question 2 Have you been tired or fatigued during the 
last two weeks?  
Question 3 Have you experienced bodily pain?  
Question 4 Have you felt sleepy during the day? 
Question 5 Have you experienced abdominal pain?  
Question 6 Has shortness of breath been a problem for 
you in your daily activities?  
Question 7 Have you not been able to eat as much as 
you would like? 
Question 8 Have you been bothered by having 
decreased strength?  
Question 9 Have you had trouble lifting or carrying 
heavy objects? 
Question 10 Have you felt anxious? 
Question 11 Have you felt a decreased level of energy? 
Question 12 Have you felt unhappy? 
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Question 13 Have you felt drowsy? 
Question 14 Have you been bothered by a limitation of 
your diet? 
Question 15 Have you been irritable? 
Question 16 Have you had difficulty sleeping at night? 
Question 17 Have you been troubled by a feeling of 
abdominal discomfort? 
Question 18 Have you been worried about the impact of 
your liver disease has on your family? 
Question 19 Have you had mood swings? 
Question 20 Have you been unable to fall asleep at 
night? 
Question 21 Have you had muscle cramps? 
Question 22 Have you been worried that your symptoms 
will develop into major problems? 
Question 23 Have you had a dry mouth?  
Question 24 Have you felt depressed? 
Question 25 Have you been worried about your 
condition getting worse? 
Question 26 Have you had problems concentrating? 
Question 27 Have you been troubled by itching? 
Question 28 Have you been worried about never feeling 
any better? 
Question 29 Have you been concerned about the 






Appendix 2: Trial schedule 
 
 Screening Treatment Follow up 











6th day of 
treatment)
7 
Visit 3  
(day 30) 












Informed consent X        
Clinical assessment2 X X X X X X X X 
Vital signs3 X X X X X X X X 
Screening blood tests4 X        
ECG X        
Standard blood tests5 X X X X X X X X 
Mandatory 
microbiology7 
X        
Abdominal USS X  X    X  
Fibroscan X     X X X 
ELF panel X   X X X X X 
CLDQ X     X X X 
G-CSF administration  Group 2 
Group 3 
      
Leukapharesis   Group 3      
Blood test for 
circulating CD34+ 




     
Blood test for 
circulating CD133+ 




     
CD133+ cell infusion   Group 3 Group 3 Group 
3 
   
Adverse effects6 X X X X X X X X 
Clinical events6  X X X X X X X 
Concomitant 
medication 
X X X X X X X X 
(1) For patients in groups 1 and 2 visits 1 and visit 2a should be combined into 1 day where possible. 
For patients in group 3, timing of visit 2a will depend on scheduling of leukapheresis. (2) All screening 
tests must be completed less than 7 days prior to randomisation and treatment and must start less than 
7 days following randomisation. Day of randomisation will be considered as day 1 for scheduling 
purposes. (3) Clinical assessment consists of complete history and examination at screening and focused 
history and relevant examination at subsequent visits. (4) Vital signs to include heart rate, blood 
pressure, temperature and weight. (5) Screening blood tests as detailed in section 5. (6) Standard blood 
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tests consist of full blood count, urea and electrolytes, liver function tests, magnesium and alanine 
aminotransferase (ALT) international normalised ratio (INR). (7) Adverse effects and clinical events 
will be monitored continuously until completion of follow-up. Serious adverse events (SAE's) will be 
reported from the date of consent. All adverse events experienced by patients will be recorded 
irrespective of the causality (see section 7). (8) Mandatory microbiological testing must be performed 
between 7 and 30 days prior to leukapheresis—HBV, HCV, HIV, human T-lymphotropic virus 1 and 2 
(HTLV-1, HTLV-2) and syphilis. (9) The first re-infusion of CD133+ (group 3 patients only) will occur 
on one occasion only between days 6 and 10. The timing will be determined by the timing of each 




Appendix 3: Search strategy used in MEDLINE, MEDLINE in Process, EMBASE 
 
1. exp Acute-On-Chronic Liver Failure/or exp Liver Diseases/or exp Liver Regeneration/or 
exp End Stage Liver Disease/or exp Liver Cirrhosis/ 
2. liver disease$. ti, ab. 
3. liver cirrhosis. ti, ab. 
4. acute-on-chronic liver failure. ti, ab. 
5. liver regenerat$. ti, ab. 
6. exp Hematopoietic Stem Cells/or exp Stem Cells/or exp Stem Cell Transplantation/or exp 
Bone Marrow/ 
7. exp Mesenchymal Stromal Cells/ 
8. stem cell$. ti, ab. 
9. exp Granulocyte Colony-Stimulating Factor/ 
10. granulocyte colony stimulating factor. ti, ab 
11. mesenchymal stromal cell. ti, ab. 
12. 1 or 2 or 3 or 4 or 5 
13. 6 or 7 or 8 or 9 or 10 or 11 
14. 12 and 13 











Types  Reason for exclusion 
Alzoubi 2013 Paper Editorial paper 
Anand  2014 Conference 
abstract 
Outcomes interested not measured 
Anand  2016 Conference 
abstract 
Outcomes interested not measured 
Annonymous  2012 Paper Review paper 
Annonymous  2014 Paper Review paper 
Bica  2012 Conference 
abstract 
Outcomes interested not measured 
Bihari  2016 Paper Outcomes interested not measured 
Brodosi  2012 Conference 
abstract 
Outcomes interested not measured 
Burganova  2015 Conference 
abstract 
Outcomes interested not measured 
Burganova  2015 Conference 
abstract 
Outcomes interested not measured 
Burganova  2017 Conference 
abstract 
Outcomes interested not measured 
Cardinale  2014 Paper Outcomes interested not measured 
Cardinale  2014 Paper Outcomes interested not measured 
Catani  2012 Conference 
abstract 
Outcomes interested not measured 
Chen HQ  2010 Paper No abstract and full text in Chinese 
Engelmann  2015 Conference 
abstract 
Outcomes interested not measured 
Engelmann  2016 Paper Acute liver failure patients included 
Kantarcioglu  2013 Conference 
abstract 
Outcomes interested not measured 
Kantarcioglu  2015 Conference 
abstract 
Outcomes interested not measured 
Kim JK 2015 Conference 
abstract 
Outcomes interested not measured 
Liu LY 2010 Paper Outcomes interested not measured 
Peng  2011 Paper Outcomes interested not measured 
Pan XN  2014 Paper Systematic review paper 
Qi X  2015 Paper Review paper 
Qin AC 2010 Paper Outcomes interested not measured 
Terai  2012 Paper Review paper 
Yao P  2005 Paper No abstract and full text in Chinese 
Yang H Z  2013 Paper No abstract and full text in Chinese 
Yang H  2015 Paper No abstract and full text in Chinese 
Yu SJ  2016 Paper No abstract and full text in Chinese 
Zheng L 2013 Paper Outcomes interested not measured 
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Appendix 5: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart of existed systematic review 
 




























Section/topic  # Checklist item  page #  page # page #  page #  page #  page #  page #  page #  page #  
TITLE           
Title  1 Identify the report as a systematic 
review, meta-analysis, or both.  
499 90 631 1405 1 166 147 673 14051 
ABSTRACT           
Structured 
summary  
2 Provide a structured summary 
including, as applicable: background; 
objectives; data sources; study 
eligibility criteria, participants, and 
interventions; study appraisal and 
synthesis methods; results; limitations; 
conclusions and implications of key 
findings; systematic review registration 
number.  
499 90 631 1405 1 166 147 673 14051 
INTRODUCTION           
Rationale  3 Describe the rationale for the review in 
the context of what is already known.  
500 90 NR 1405 2 NR 148 674 14052 
Objectives  4 Provide an explicit statement of 
questions being addressed with 
reference to participants, interventions, 
comparisons, outcomes, and study 
design (PICOS).  
500 90 632 1406 2 167 148 674-
675 
14052 
METHODS           
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Section/topic  # Checklist item  page #  page # page #  page #  page #  page #  page #  page #  page #  
Protocol and 
registration  
5 Indicate if a review protocol exists, if 
and where it can be accessed (e.g., 
Web address), and, if available, 
provide registration information 
including registration number.  
NR NR NR NR NR NR NR NR NR 
Eligibility 
criteria  
6 Specify study characteristics (e.g., 
PICOS, length of follow-up) and report 
characteristics (e.g., years considered, 
language, publication status) used as 












7 Describe all information sources (e.g., 
databases with dates of coverage, 
contact with study authors to identify 
additional studies) in the search and 
date last searched.  





Search  8 Present full electronic search strategy 
for at least one database, including any 






NR 674 NR 
Study selection  9 State the process for selecting studies 
(i.e., screening, eligibility, included in 
systematic review, and, if applicable, 
included in the meta-analysis).  
500-
501 

































Section/topic  # Checklist item  page #  page # page #  page #  page #  page #  page #  page #  page #  
Data collection 
process  
10 Describe method of data extraction 
from reports (e.g., piloted forms, 
independently, in duplicate) and any 
processes for obtaining and confirming 
data from investigators.  






2 NR 149 675 14052 
Data items  11 List and define all variables for which 
data were sought (e.g., PICOS, funding 
sources) and any assumptions and 
simplifications made.  
NR NR NR 1406 2 NR 148-
149 
NR NR 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing 
risk of bias of individual studies 
(including specification of whether this 
was done at the study or outcome 
level), and how this information is to 

















13 State the principal summary measures 
(e.g., risk ratio, difference in means).  
500 91 635 1406 2 167-
168 
149 675 14052 
Synthesis of 
results  
14 Describe the methods of handling data 
and combining results of studies, if 
done, including measures of 
consistency (e.g., I2) for each meta-
analysis.  


































Section/topic  # Checklist item  page #  page # page #  page #  page #  page #  page #  page #  page #  
Risk of bias 
across studies  
15 Specify any assessment of risk of bias 
that may affect the cumulative 
evidence (e.g., publication bias, 





















16 Describe methods of additional 
analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, 
indicating which were pre-specified.  
503-
505 




NR NR NR 
RESULTS           
Study selection  17 Give numbers of studies screened, 
assessed for eligibility, and included in 
the review, with reasons for exclusions 



































18 For each study, present characteristics 
for which data were extracted (e.g., 
study size, PICOS, follow-up period) 

























Risk of bias 
within studies  
19 Present data on risk of bias of each 
study and, if available, any outcome 
level assessment (see item 12).  


















































20 For all outcomes considered (benefits 
or harms), present, for each study: (a) 
simple summary data for each 
intervention group (b) effect estimates 
and confidence intervals, ideally with a 




















21 Present the main results of the review. 
If meta-analyses are done, include for 
each meta-analysis, confidence 



















Risk of bias 
across studies  
22 Present results of any assessment of 
risk of bias across studies (see Item 
15).  


















23 Give results of additional analyses, if 
done (e.g., sensitivity or subgroup 












DISCUSSION           
Summary of 
evidence  
24 Summarize the main findings including 
the strength of evidence for each main 











































Section/topic  # Checklist item  page #  page # page #  page #  page #  page #  page #  page #  page #  
key groups (e.g., healthcare providers, 
users, and policy makers).  
Limitations  25 Discuss limitations at study and 
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Appendix 6:  Data collection proforma 
 
       Study Reference: ……………………  
       Reviewer: ……………………………………… 
Inclusion criteria full text: 
Include:  YES  □ NO    □  UNSURE         □ 
Type of study:  
………………………………………………………………………………………………
……… 
1. Population:  YES □  NO □ UNSURE        □ 
i. Adult patients (>18 yrs)  □      
ii. Liver cirrhosis/fibrosis (chronic liver disease/damage/End stage liver disease) – 
any cause □ 
iii. Acute on chronic liver failure/disease – as defined by the author  □ 
 
2. Intervention:   YES  □  NO □ UNSURE        □ 
 
To include any dose, duration and route of administration  
 
1) Bone marrow derived stem cells (with or without GCSF)                                          
1a: Haematopoietic stem cells □                                               
1b: Mesenchymal stem cells □                                                           
1c: Mononuclear cells □                                                                
1d: other type, name……………………………                                
              1e: GCSF given or not? (Y/N) Y □         N □                                                
 
2) Non-bone marrow derived cells or allogenic from another source (if yes) 
Type of stem cells…………………………………………………….       □ 
 
3) Granulocyte colony stimulating factor (GCSF) only            □ 
 
 
Please state dose, duration and route of administration 
…………………………………………………………………………………… 
 
3. Comparison:    Yes □   No □  Unsure □ 
Standard therapy   Yes □   No □ 
No standard therapy   Yes □   No □ 
 
4. Outcomes:   Yes □   No □  Unsure □ 
Minimum FU of 4 weeks  Yes □   No □ 




i) Liver function tests   Yes □   No □    
  
ii) Model for End stage liver disease  Yes □   No □ 
iii) Child Pugh Score    Yes □   No □ 
iv) Survival      Yes □   No □ 
v) Quality of life    Yes □   No □ 
Exclusion criteria full text: (exclude if any of it is yes) 
i. Children      Yes □   No □    
   
ii. Acute liver failure     Yes □   No □     
iii. Cancer of any form (as unsure how stem cell therapy affects cancer OR how cancer 
affects stem cell therapy) 
Yes □   No □     
iv. Any article that does not state cirrhosis/fibrosis/CHRONIC liver failure e.g. in 
patients with acute alcoholic hepatitis, where they did not have any evidence of 
underlying liver fibrosis or cirrhosis.  
Yes □   No □     
v. Follow up less than 4 weeks     Yes □   No □     
vi. Cellular morphology/histology outcomes ONLY Yes □   No □     
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